title: An Open-Label Safety Study of Patients with Severe Eosinophilic Asthma Who Were Previously Enrolled in the Reslizumab Open Label Extension Study C38072/3085

lead_sponsor: Teva Branded Pharmaceutical Products R&D, Inc.


title:
Tamsulosin to prevent the failures of early bladder catheter removal after acute urinary retention in elderly women hospitalized for an acute medical problem

 Tamsulosine pour prévenir les échecs de retrait de sonde vésicale précoce après rétention aiguë d’urines chez la femme âgée hospitalisée pour un problème médical aigu

acronym: TAMSU

source: euctr

lead_sponsor: ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP)

study_type: Interventional

status: Prematurely Ended

lead_sponsor_type: academique

status_simplified: Unknown


title: Pilot study to assess efficacy and safety of Sofosbuvir/Ledipasvir (GS-5885) fixed-dose combination with Ribavirin in NS3/4A protease inhibitor-experienced subjects with HCV genotype 1 infection and HIV co-infection

lead_sponsor: INSERM-ANRS

status: Ongoing

status_simplified: Ongoing


title:
Effect of impact of PCSK9 inhibitor on coronary microvascular dysfunction in patients with atherosclerotic cardiovascular disease proved by myocardial ischemia and needing coronarography.

  Évaluation de l’impact des anticorps monoclonaux anti--proprotéine convertase subtilisine/kexine de type 9 (PCSK9), sur le dysfonctionnement microvasculaire coronarien chez les patients atteints d’une maladie cardiovasculaire athérosclérotique, prouvée par une ischémie myocardique nécessitant une coronarographie.

acronym:
MICROPROTECT

 MICROPROTECT

lead_sponsor: University Hospital Grenoble


title: Influence of apelin on insulin sensitivity in type 2 diabetic volunteers

acronym: APELINS 2

lead_sponsor: CHU TOULOUSE

status: Completed

status_simplified: Completed


title:
Prospective randomized versus placebo study evaluating the feasibility of plasma therapy in septic shock induced coagulopathy

 Étude prospective randomisée versus placebo évaluant la faisabilité d'une plasmathérapie dans la coagulopathie induite par le choc septique

acronym:
PLASMA-faisa

 PLASMA-faisa

lead_sponsor: Hôpitaux Universitaires de Strasbourg


title:
Adaptation to neonatal life  after an anesthetic protocol using remifentanil for general anesthesia for caesarean section in a context of prematurity - REAGI Protocol (Remifentanil for General Anesthesia in the context of Immaturity)

 Répercussions sur l'adaptation à la vie néonatale de l'utilisation du rémifentanil au cours d'un protocole d'anesthésie générale pour césarienne dans un contexte de prématurité – Protocole REAGI (REmifentanil pour Anesthésie Générale en contexte d'Immaturité)

acronym:
REAGI

 REAGI

lead_sponsor: CHU- Hôpitaux de Rouen


title:
Phase II study of first line treatment of Chronic Graft versus Host Disease with Arsenic Trioxide

 Étude de phase II du traitement en première ligne de la réaction chronique du greffon contre l’hôte par le trioxyde d’arsenic

acronym:
GvHD-ATO

 GvHD-ATO

lead_sponsor: Medsenic

lead_sponsor_type: industriel


title: Etude de la cinétique de la céfazoline et de la clindamycine dans l’antibioprophylaxie pour césarienne programmée avec une injection avant l’incision.

acronym: ATB-césarienne

lead_sponsor: CHU de Clermont-Ferrand


title:
A PHASE 2, OPEN-LABEL, SINGLE-ARM ROLLOVER STUDY TO EVALUATE LONG-TERM SAFETY IN SUBJECTS WHO PARTICIPATED IN OTHER CELGENE SPONSORED CC-486 (ORAL AZACITIDINE)
 CLINICAL TRIALS IN SOLID TUMORS AND HEMATOLOGICAL DISORDERS

lead_sponsor: Celgene Corporation


title:
Efficacy of  parietal continous infiltration of local anesthesic on diaphragmatic function after upper abdominal surgery through a subcostal incision

 Efficacité de l’analgésie par infiltration pré péritonéale continue d’anesthésique local sur la fonction diaphragmatique après chirurgie abdominale sus-mésocolique par voie sous costale

acronym:
CATPAR

 CATPAR

lead_sponsor: CHU de Rouen


title: Evaluation of the effect of Atomoxetine on impulsive state of High impulsive Tourette’s patients.

acronym: ATO-TS

lead_sponsor: CHU DE POITIERS


title:
Multicenter double-blind randomized clinical trial assessing efficacy and safety of exenatide in the treatment of hypothalamic obesity after craniopharyngioma therapy.

 Essai multicentrique randomisé en double insu évaluant l’efficacité et la tolérance du traitement par exénatide dans l’obésité hypothalamique de l’adulte secondaire au traitement du craniopharyngiome

acronym:
CRANIOEXE

 CRANIOEXE

lead_sponsor: CHU de Bordeaux


title: ETUDE TRANSCRIPTOMIQUE DE LA REPONSE AU MINOXIDIL CHEZ L'HOMME ALOPECIQUE

lead_sponsor: L'OREAL


title: Evaluation de l’efficacité de 3 stratégies de prise en charge au long cours des symptômes de reflux gastro-oesophagien en médecine générale : étude multicentrique, randomisée, en ouvert, réalisée en groupes parallèles

acronym: MAESTRO

lead_sponsor: AstraZeneca S.A.S


title: Effets du moclobémide sur le profil d'activation cérébrale de patients dépressifs âgés lors de tâches cognitives et émotionnelles, en référence à des sujets témoins. Etude ouverte, multicentrique, chez le patient âgé présentant un épisode dépressif majeur et traité par moclobémide pendant 6 semaines

lead_sponsor: BIOCODEX


title: Cathéter au canal des adducteurs sous sartorial (KTSS) versus cathéter fémoral (KTF) dans une démarche de réhabilitation rapide après prothèse totale de genou : Etude contrôlée, randomisée.

acronym: KTSS

lead_sponsor: Centre Hospitalier Départemental Vendée de la Roche sur Yon


title: Essai en ouvert, randomisé et multicentrique évaluant l’efficacité et la tolérance de l’association de l’Enfuvirtide en cure d’induction de 3 mois à un traitement optimisé (TO) comprenant au moins 2 molécules pleinement actives, versus TO seul, chez des patients VIH-1 en échec virologique et naïfs d’Enfuvirtide, avec réintensification possible du traitement optimisé par « séquences » de 3 mois d’Enfuvirtide en cas de nouvel échec virologique

acronym: INNOVE

lead_sponsor: Roche


title:
Phase II study to evaluate the efficacy of upfront obinutuzumab in mantle cell lymphoma patients treated by DHAP followed by autologous transplantation plus obinutuzumab maintenance then MRD driven maintenance

 Etude de phase II évaluant l’efficacité de l’obinutuzumab chez des patients présentant un lymphome du manteau traité par DHAP puis par greffe autologue plus entretien par obinutuzumab suivi d’un entretien selon les résultats de la MRD

lead_sponsor: LYSARC


title: Etude ouverte, multicentrique, de 24 semaines, évaluant l'efficience clinique de la forme Exelon patch 10 cm2 chez des patients avec une maladie d'Alzheimer (MMSE 10-26)

acronym: EXTRA

lead_sponsor: NOVARTIS PHARMA SAS


title:
ABATACEPT VERSUS TOCILIZUMAB BY SUBCUTANEOUS ADMINISTRATION FOR THE TREATMENT OF RHEUMATOID ARTHRITIS IN TNF ALPHA INHIBITOR INADEQUATE RESPONDER PATIENTS: A RANDOMIZED, OPEN-LABELED, SUPERIORITY TRIAL.

 ABATACEPT VERSUS TOCILIZUMAB PAR VOIE SOUS-CUTANEE DANS LE TRAITEMENT DE LA POLYARTHRITE RHUMATOÏDE CHEZ DES PATIENTS EN ECHEC D’UN PREMIER TRAITEMENT PAR ANTI-TNF ALPHA : ESSAI DE SUPERIORITE, RANDOMISE, OUVERT

acronym:
SUNSTAR

 SUNSTAR

lead_sponsor: Groupement des Hôpitaux de l’Institut Catholique de Lille


title: Oral alendronate for osteoporosis treatment in non-walking children with cerebral palsy

lead_sponsor: CHU de Nice


title: Comparaison de deux stratégies d’administration de l’albumine humaine chez des malades agressés de réanimation présentant une hypoalbuminémie ≤ 20g/L.

acronym: ALBALSACE

lead_sponsor: Hôpitaux Universitaires de Strasbourg


title: AMBIZYGO. Etude de phase II de l'efficacité d'une posologie initiale élevée d'amphotéricine B liposomale (AmBisome) (10mg/kg/j) dans le traitement des zygomycoses

acronym: AMBIZYGO

lead_sponsor: ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP)


title:
PRODIGE 50 - ASPIK : French prospective randomised double blind study on aspirin versus placebo in resected colon cancer with PI3K mutation stage III or II high risk

 PRODIGE 50 - ASPIK: Etude prospective randomisée en double aveugle aspirine versus placebo chez les patients opérés d’un adénocarcinome du colon stade III ou II à haut risque de récidive avec mutation PI3K.

acronym: PRODIGE 50 - ASPIK FRENCH

lead_sponsor: CHU-Hôpitaux de Rouen


title: "Etude d'évaluation du profil d'efficacité/tolérance de 2 doses de dropéridol intraveineux dans la prévention des nausées et des vomissements post-opératoires (NVPO) liés à la chirurgie de la thyroïde"

acronym: DIPAVO


title:
A study of patient preference between ODM-201 and Enzalutamide in men with metastatic castrate-resistant prostate cancer

 Etude de préférence des patients entre l’ODM-201 et l’Enzalutamide chez des hommes atteints d’un cancer de la prostate métastatique résistant à la castration

acronym: ODENZA Preference

lead_sponsor: Gustave Roussy


title: Etude de pharmacocinétique de population du linézolide chez des patients de réanimation présentant une infection sévère à Staphylocoque doré méticillino-résistant

lead_sponsor: CHU de Toulouse


title: Effectiveness of oral corticosteroids in unilateral recurrent laryngeal nerve palsy after thyroidectomy


title:
A randomized, double-blind, placebo-controlled trial comparing the efficacy and tolerance of sodium oxybate in patients affected with idiopathic hypersomnia.

 Etude bi-centrique contrôlée randomisée en double aveugle évaluant l'efficacité et la tolérance de l'oxybate de sodium chez les patients atteints d'hypersomnie idiopathique.

acronym:
SODHI

 SODHI

lead_sponsor: University Hospital of Montpellier


title: A Phase I/II, Open Label Multi-Centre Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of the JAK2 inhibitor AZD1480 Administered Orally to Patients with Primary Myelofibrosis (PMF) and Post-Polycythaemia Vera/Essential Thrombocythaemia Myelofibrosis (Post-PV/ET MF)

lead_sponsor: AstraZeneca AB


title: A Pragmatic randomized study to evaluate the comparative effectiveness of Akynzeo® and Standard of care (including Emend®) for the prevention of nausea and vomiting (CINV) in cancer patients receiving moderately emetogenic chemotherapy in France

lead_sponsor: VIFOR FRANCE


title:
Pilot study on doxorubicin kinetic distribution during arterial chemoembolization

 Etude pilote de la cinétique de distribution de la Doxorubicine lors de la chimio-embolisation artérielle

acronym: CINEDOXO


title:
The use of FES-PET imaging as a tool to detect a possible reversion of Estrogen Receptor (ER)-α status in patients with metastatic breast cancer HER2 + and ERα neg treated with trastuzumab + pertuzumab + taxane.

 La TEP-FES comme outil de détection d’une possible réversion du statut REα chez des patientes présentant un cancer du sein métastatique HER2+ et REα neg traitées par trastuzumab + pertuzumab + taxane.

acronym:
REVER

 REVER

lead_sponsor: INSTITUT CLAUDIUS REGAUD


title: Prospective comparison of 18F-choline PET/CT and 18F-FDG PET/CT in the initial work-up of Multiple Myeloma

acronym: MYELOCHOL

lead_sponsor: CHU de Bordeaux


title: Etude de l'efficacité de CIRKALM crème versus placebo dans le traitement des douleurs anales

lead_sponsor: PIERRE FABRE MEDICAMENT


title:
Non inferiority multicenter phase III randomized trial comparing preoperative chemotherapy only to chemoradiotherapy for locally advanced resectable rectal cancer (intergroup FRENCH-GRECCAR- PRODIGE)

 Essai randomisé de phase III multicentrique comparant la chimiothérapie seule à la radiochimiothérapie préopératoire pour les cancers du rectum localement évolués d’emblée résécables (intergroupe FRENCH-GRECCAR-PRODIGE)

lead_sponsor: ASSISTANCE PUBLIQUE - HÔPITAUX DE PARIS (AP-HP)


title: Pilot study of Lapatinib (Tyverb®) in néoadjuvant treatment for patients with locally bladder carcinoma before cystectomy

acronym: LAPAINBLAD


title:
Efficacy and tolerance of the association of MTX and phototherapy versus phototherapy in adults with progressive vitiligo : a randomized double blind prospective study (METVI)

 Efficacité et tolérance de la combinaison méthotrexate plus photothérapie et de la photothérapie seule chez les patients atteints d’un vitiligo progressif: étude de phase 2 (METVI)

acronym:
METVI

 METVI


title: Etude prospective ouverte de l'efficacité du leflunomide dans le traitement de la pemphigoïde bulleuse en association aux dermocorticoïdes.

acronym: ARABUL

lead_sponsor: CHU de Limoges


title:
Intérêt de l’administration de charbon Activé pour les patients ayant un geste invasif reporté dû à un traitement Anticoagulant Oral Direct

 Intérêt de l’administration de charbon Activé pour les patients ayant un geste invasif reporté dû à un traitement Anticoagulant Oral Direct

acronym: CACAOD

lead_sponsor: CHU Angers


title: Pharmacocinétique de l’association pipéracilline-tazobactam chez les patients septiques, en insuffisance rénale oligo-anurique, traités par hémodiafiltration veino-veineuse continue

lead_sponsor: CHU de TOULOUSE


title: ETUDE DE PHASE II DU THALIDOMIDE DANS LES MASTOCYTOSES

lead_sponsor: CHU Amiens


title:
Intrathecal Rituximab in Progressive Multiple Sclerosis

 Effet du Rituximab intrathécal dans la SEP progressive

acronym:
EFFRITE

 EFFRITE

lead_sponsor: Centre Hospitalier de Pau


title:
« Mesenchymal stromal cells treatment in Lyell syndrome: A pilot phase 1-2 open trial”

 Cellules stromales mésenchymateuses dans le traitement du syndrome du Lyell : une étude de phase pilote I-II en ouvert

acronym: LYSYME

lead_sponsor: ASSISTANCE PUBLIQUE-HOPITAUX DE PARIS


title: Etude chez le sujet volontaire sain de l’effet de carbolevure versus placebo sur la fermentation intestinale induite par l’ingestion de lactulose.

lead_sponsor: Pierre Fabre Médicament


title: Etude randomisée, en double aveugle, comparant l’efficacité et la tolérance de la méthylprednisolone administrée à forte dose par voie orale ou par voie intraveineuse dans le traitement des poussées de sclérose en plaques

acronym: COPOUSEP

lead_sponsor: CHU Rennes


title: EVALUATION DE LA REPONSE IMMUNITAIRE CONTRE LA SOUCHE  DE NEISSERIA MENINGITIDIS B:14,P1.7,16  CHEZ LES SUJETS VACCINES PAR MenBVac

acronym: Immunogénicité MenBVac

lead_sponsor: CHU - Hôpitaux de Rouen


title:
Interest in the administration of Dornase alpha aerosol in ARDS secondary to respiratory infection by the coronavirus SRASCoV-2 / COVID-19

 Intérêt de l'administration de Dornase alpha en aérosol dans le SDRA secondaire à une infection respiratoire par le coronavirus SRASCoV-2 / COVID-19

acronym:
COVID19-COVIDornase

 COVID19-COVIDornase

lead_sponsor: Hôpital Fondation Adolphe de Rothschild


title: Evaluation des effets de l’ivabradine 5 mg et 7.5 mg en 2 prises par jour par voie orale chez des patients insuffisants cardiaques avec une hypertension artérielle insuffisamment équilibrée par Perindopril 4 mg/j par voie orale. Etude ouverte, multicentrique

lead_sponsor: Institut de Recherches Internationales Servier


title:
FOLFIRINOX VERSUS PLATINUM - ETOPOSIDE AS FIRST LINE CHEMOTHERAPY FOR METASTATIC GRADE 3 POORLY DIFFERENTIATED NEUROENDOCRINE CARCINOMA OF GASTRO ENTERO PANCREATIC AND UNKNOWN PRIMARY ASSOCIATED WITH MOLECULAR PROFILING FOR THERAPEUTIC TARGETS & PREDICTIVE BIOMARKERS IDENTIFICATION

 A multi-centre, randomized, comparative phase II study

 FOLFIRINOX VERSUS PLATINE - ÉTOPOSIDE EN PREMIÈRE LIGNE DE TRAITEMENT DES CARCINOMES NEUROENDOCRINES PEU DIFFERENCIÉS DE GRADE 3 MÉTASTATIQUES GASTRO-ENTERO-PANCRÉATIQUE ET DE PRIMITIF INCONNU ASSOCIÉ A L’ÉTABLISSEMENT D’UN PROFIL MOLÉCULAIRE.
 Étude de phase II multicentrique, randomisée et comparative

acronym:
FOLFIRINEC

 FOLFIRINEC

lead_sponsor: CHU DIJON


title: Confirmation clinique d'une interaction pharmacodynamique entre tropisétron et paracétamol

lead_sponsor: CHU de Clermont-Ferrand


title:
RAR-Immune: A randomised, comparative, prospective, multicentre study of the efficacy of nivolumab + ipilimumab versus pazopanib alone in patients with metastatic or unresectable advanced sarcoma of rare subtype

 RAR-Immune: Etude randomisée, comparative, prospective et multicentrique de l’efficacité du nivolumab + ipilimumab versus pazopanib seul chez des patients atteints d’un sous-type rare de sarcome avancé non résécable ou métastatique

lead_sponsor: Centre Léon Bérard


title:
THE IMMUNOTHERAPY PLEURAL 5-ALA PDT “IMPALA” trial: Intrapleural Photodynamic Therapy by Video-Assisted Thoracoscopy followed by Anti-PD-1 NIVOLUMAB in Patients with Malignant Pleural Mesothelioma- a pilot study

 Arial

lead_sponsor: CHU de LILLE


title: A prospective, multicenter, open-label, uncontrolled, two-parallel group, phase 1/2 study to evaluate safety and efficacy of masitinib at 9 mg/kg/day in monotherapy and in combination with dacarbazine in the treatment of patients with non-resectable or metastatic stage 3 or stage 4 melanoma not carrying a mutation in the juxta membrane domain of c-kit

lead_sponsor: AB SCIENCE


title: Clinical trial assessing the immunogenicity of an anti-pneumococcal combined vaccination strategy in adult patients treated for an acute leukemia or a lymphoma

lead_sponsor: CHU DE POITIERS


title: étude cas-témoins comparant l'efficacité d’une combinaison thérapeutique contenant l'inhibiteur de l'intégrase raltégravir (400 mg x 2) ou une combinaison thérapeutique ne contenant pas le raltégravir sur la diminution de l'ADN proviral chez des sujets prétraités présentant une infection par le VIH-1 avec une charge virale détectable

acronym: IN-DEEP

lead_sponsor: STOP SIDA


title: Recombinant InterLeukin-7 (CYT107) to Improve clinical outcomes in lymphopenic pAtients with COVID-19 infection

acronym: ILIAD 7

lead_sponsor: RevImmune


title: A phase II study evaluating the efficacy and safety of Lenalidomide (Revlimid®) with or without Epoetin beta (NeoRecormon®) in transfusion-dependent ESA-resistant patients with IPSS low- and intermediate-1 risk myelodysplastic syndromes without chromosome 5 abnormality

lead_sponsor: Groupe Francophone des Myélodysplasies


title:
Using INDOcyanine green to analyse ovarian vascularization after ovarian laparoscopic CYStectomy,  Diagnostic study of feasibility.

 Étude de la vascularisation ovarienne après traitement coelioscopique des KYStes ovariens, grâce à l’injection de vert d’INDOcyanine. Étude diagnostique de faisabilité.

acronym:
KYSINDO

 KYSINDO

lead_sponsor: CHU CLERMONT FERRAND - DRCI


title: Etude prospective, multicentrique contrôlée vs. placebo, randomisée, en double Insu, évaluant les bénéfices et risques d'un traitement précoce par faibles doses de corticoïdes, des pneumonies graves dues à la grippe A/H1N1v 2009, associé à un traitement anti-viral.

acronym: CORTIFLU

lead_sponsor: ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP)


title: A randomized, exploratory, open-label 48-week trial with a 2-week Pre-Treatment Phase to investigate the pharmacokinetics, safety, tolerability and antiviral activity of etravirine (ETR) in combination with ritonavir-boosted atazanavir (ATV/rtv) and 1 NRTI in treatment-experienced HIV-1 infected subjects

lead_sponsor: Tibotec Pharmaceuticals


title: Protocole IFM 2008 :  Primo-traitement des patients de moins de 65 ans atteints de myélome

lead_sponsor: CHU de TOULOUSE


title: Double blind, multicentric, randomized, placebo-controlled trial, evaluating the efficacy of 24-month of bezafibrate in primary sclerosing cholangitis with persistent cholestasis despite ursodeoxycholic acid therapy

acronym: BEZASCLER


title: Determination De La Dose Efficace De L-Bupivacaine Pour Rachianesthésie En Chirurgie Proctologique : Étude Comparative Prospective Randomisée En Double Aveugle.

acronym: CHIRO

lead_sponsor: Hospices Civils de Lyon


title:
A Double-blind Randomized non-inferiority Trial of erector spinae block (ESP) versus paravertebral block (PVB) before Breast Cancer Surgery: Effects on acute Postoperative Pain

 Essai clinique randomisé de non-infériorité, multicentrique en double aveugle, évaluant l’effet du bloc érecteur (ESP) versus bloc paravertébral (BPV) sur la douleur aiguë après chirurgie carcinologique du sein

acronym:
ER-One

 ER-One

lead_sponsor: INSTITUT CURIE


title: Etude de phase 3 randomisée multicentrique étudiant l’effet de l’addition de l’anticorps monoclonal Gemtuzumab Ozogamicin (Mylotarg) utilisé en doses fractionnées au traitement d’induction et de consolidation par Daunorubicine et Aracytine chez les patients atteints de Leucémie Aigue Myéloide (LAM) et âgés de 50 à 70 ans.

acronym: Mylofrance 3

lead_sponsor: CH-Versailles


title: AN  INVESTIGATOR BLIND PARALLEL GROUP  VEHICLE  CONTROL STUDY COMPARING THE EFFICACY AND SAFETY OF CD 5024  1%  CREAM  WITH  METRONIDAZOLE 0.75% CREAM IN SUBJECTS WITH PAPULOPUSTULAR ROSACEA OVER 16 WEEKS TREATMENT

lead_sponsor: GALDERMA R&D SNC


title: An open-label, multi-centre, clinical study to collect information on the clinical use of argatroban in patients with heparin induced thrombocytopenia (HIT) Type II who require parenteral antithrombotic therapy.

lead_sponsor: Mitsubishi Tanabe Pharma Corporation


title:
Nitrous Oxide in Resistant Depression in Elderly Subjects: A Randomized, Double-blind, Comparator Trial

 Protoxyde d’Azote dans la Dépression Résistante du Sujet Âgé: un essai randomisé en double aveugle avec comparateur

acronym:
PROTO-BRAIN

 PROTO-BRAIN

lead_sponsor: CHRU TOURS


title: Etude de phase II multicentrique étudiant l’efficacité de la doxorubicine associée à de la trabectedine (Yondelis)  en première ligne dans le traitement des patients présentant un léiomyosarcome métastatique (utérin ou des tissus mous) et/ou en rechute inopérable

lead_sponsor: Institut Gustave Roussy


title:
Etude pharmacocinétique de l’apomorphine en perfusion sous-cutanée continue diurne chez le patient parkinsonien équilibré sous traitement

 Etude pharmacocinétique de l’apomorphine en perfusion sous-cutanée continue diurne chez le patient parkinsonien équilibré sous traitement

acronym: PHARM-APO

lead_sponsor: CHU Rennes


title: A survey on the success of inhibitor elimination using individualized concentrate selection and controlled immune tolerance induction

acronym: OBSITI

lead_sponsor: CHU de Saint-Etienne


title: Réduction de la reconsolidation du souvenir traumatique par le propranolol : un essai pilote.

acronym: ReducTrauma

lead_sponsor: CHU Toulouse


title: Effet d'un antagoniste du récepteur de l'endothéline 1 (Sitaxentan, Thelin) sur le remodelage bronchique au cours de l'asthme sévère avec obstruction bronchique persistante.

acronym: Entholéine et remodelage bronchique dans l'asthme sévère

lead_sponsor: INSERM


title: ETUDE MULTICENTRIQUE FAG-3 : TRAITEMENT PAR CARBOPLATINE DES PATIENTES DE PLUS DE 70 ANS ATTEINTES DE CANCER AVANCE DE L’OVAIRE : PREDICTION  DE LA VULNERABILITE INDIVIDUELLE PAR UNE EVALUATION PSYCHO-GERIATRIQUE COMBINEE A UNE ETUDE EPIGENETIQUE (TELOMERES)

acronym: FAG 3

lead_sponsor: HOSPICES CIVILS DE LYON


title: Etude de phase I associant la rapamycine et l’irinotecan dans toutes tumeurs solides réfractaires de l’enfant

acronym: RAPIRI

lead_sponsor: Hôpitaux Universitaires de Strasbourg


title: Efficacy and safety of sodium cromolyn eye drops compared with placebo eye drops in patients with a history of allergic conjunctivitis using the Conjunctival Allergen Challenge model.

lead_sponsor: Laboratoires Théa


title: Intérêt de la mesure de l’activité calcineurine dans le suivi thérapeutique du tacrolimus chez des patients transplantés rénaux

lead_sponsor: ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP)


title: Essai multicentrique évaluant  l'effet de la cystéamine sur le BDNF sérique dans la maladie de Huntington.

acronym: BDNF-HD

lead_sponsor: Centre Hospitalier Universitaire d'Angers


title: Evaluation du système noradrénergique dans l’altération de la perception douloureuse chez le patient Parkinsonien

acronym: DOULOX

lead_sponsor: CHU de Toulouse


title: Recherche d’antagonisme entre antiémétiques (dropéridol, ondansétron, dexaméthasone) et paracétamol dans l’analgésie postopératoire des thyroïdectomies

lead_sponsor: Centre Hospitalier Régional et Universitaire de Lille


title: Evaluation of the impact of physical reconditioning associated with specific nutritional supplementation in obese patients suffering of metabolic syndrome.

acronym: OBEFITT

lead_sponsor: CHU-HOPITAUX DE ROUEN


title: Comparaison du nicotinamide et du sevelamer hydrochloride sur le contrôle de la phosphatémie des hémodialysés chroniques

acronym: RENANIC

lead_sponsor: CHU d'Amiens


title: COMBINA. Efficacité et tolérance des bithérapies oseltamivir + zanamivir ou oseltamivir + amantadine en comparaison avec la monothérapie oseltamivir  dans le traitement de la grippe saisonnière A

acronym: COMBINA


title: Etude multicentrique, randomisée de non infériorité de deux stratégies thérapeutiques chez des enfants atteints de toxoplasmose congénitale

acronym: TOSCANE

lead_sponsor: CHU DIJON


title: ETUDE DE PHASE II D’UN CONDITIONNEMENT SUB-MYELOABLATIF A TOXICITE REDUITE AVANT ALLOGREFFE DE CELLULES SOUCHES HEMATOPOÏETIQUES DANS LE TRAITEMENT DES HEMOPATHIES MALIGNES

lead_sponsor: CHU de Nantes


title: Etude contrôlée, randomisée en double aveugle versus placebo de l’efficacité de la spécialité homéopathique BRN-01 dans le traitement des bouffées de chaleur de la femme ménopausée

lead_sponsor: LABORATOIRES BOIRON


title: Evaluation de la tolérance d'une administration intra-nasale d'ocytocine chez des nourrissons présentant un syndrome de Prader-Willi et de son effet sur la succion et la prise alimentaire.

acronym: OTBB

lead_sponsor: Centre Hospitalier de Toulouse


title: Evaluation de l'association irinotécan/bévacizumab utilisée en néo-adjuvant et en adjuvant d'une radiochimiothérapie avec témozolomide concomitant pour les glioblastomes non résécables. Etude de phase II randomisée avec comparaison à une radiochimiothérapie avec témozolomide concomitant et adjuvant

acronym: GBM-ANOCEF 2008-01

lead_sponsor: Centre Georges François Leclerc


title: Etude ARCTIC Comparaison randomisée 1/ d'un traitement antiplaquettaire ajusté par monitoring à un traitement standard à dose fixe pour stenting coronaire avec DES, et 2/ d'un arrêt versus poursuite d'un traitement antiplaquettaire double un an après stenting

acronym: ARCTIC


title: A phase I/II study of the efficacy and safety of an intensified schedule of Azacitidine (Vidaza®) in intermediate-2 and high risk MDS patients

acronym: GFM-Aza intensif

lead_sponsor: Groupe Francophone des Myélodysplasies


title: Evaluation de l’arrêt du traitement immunosuppresseur d’entretien après 2 ans dans les glomérulonéphrites lupiques prolifératives

acronym: etude WIN LUPUS

lead_sponsor: ASSISTANCE PUBLIQUE HOPITAUX DE MARSEILLE


title: A Phase 2 Trial of MLN8237, an Oral Aurora A Kinase Inhibitor, in Adult Patients with Acute Myelogenous Leukemia and High-Grade Myelodysplastic Syndrome

lead_sponsor: Millennium Pharmaceuticals, Inc.


title: Etude pilote, prospective, multicentrique, randomisée, en ouvert, comparant deux protocoles d’immunosuppression utilisant en traitement d’induction : soit un anticorps monoclonal antirécepteur de l’Interleukine 2 (Simulect®), soit des globulines antilymphocytaires (ATG® Frésénius), associés à une trithérapie Prograf®, Myfortic® et corticoïdes, pour la prévention du rejet chez les adultes transplantés rénaux immunisés de novo.

acronym: SATIR

lead_sponsor: CHU Toulouse


title: A Multicenter, Randomized, Open-Label, Active-Controlled Pilot Study to Evaluate the Safety and Antiretroviral Activity of Unboosted Atazanavir BID Plus Raltegravir BID and Boosted Atazanavir QD in Combination with Tenofovir/Emtricitabine QD in Treatment Naive HIV-Infected Subjects

lead_sponsor: Bristol-Myers Squibb International Corporation


title: Essai de phase II évaluant l’effet curatif de la pravastatine chez des patients présentant une fibrose cutanée et sous-cutanée radio-induite établie

acronym: PravaCUR

lead_sponsor: Institut Gustave Roussy


title: EVALUATION DE LA CAPTATION D’UN RADIOLIGAND DES TRANSPORTEURS DE LA DOPAMINE CHEZ DES SUJETS ATTEINTS DE LA MALADIE DE PARKINSON ET PRESENTANT OU NON DES DOULEURS EN RAPPORT AVEC CETTE PATHOLOGIE

acronym: dénervation dopaminergique et douleur dans la maladie de Parkinson


title: Evaluation de l’entretien de l’anesthésie générale sous Xénon comparé au Desflurane au cours de l’endartérectomie carotidienne, étude prospective, randomisée et comparative.

lead_sponsor: CHU de Poitiers


title: Etude en double insu des effets du gallopamil sur le remodelage musculaire lisse bronchique chez l'asthmatique sévère

acronym: Remodel'asthme

lead_sponsor: CHU de Bordeaux


title: Effets de l’administration orale d'arginine sur le métabolisme protéique intestinal chez des patients porteurs d’une iléo-jéjunostomie après résection intestinale étendue.

acronym: Argiléo

lead_sponsor: CHU - Hôpitaux de Rouen


title: Essai de phase III comparant la perfusion isolée pelvienne (PIP) avec du TNF-α 0,3 mg et du melphalan 1,5 mg/kg versus traitement standard dans les tumeurs pelviennes localement évoluées d’origine gynécologique ou digestive.

acronym: PIP 2


title: ETUDE PILOTE SUR L’EFFICACITE ET LA TOLERANCE DES INJECTIONS INTRA-VITREENNES DE LUCENTIS (RANIBIZUMABÒ) A LA PHASE INITIALE DES OCCLUSIONS DE LA VEINE CENTRALE DE LA RETINE

lead_sponsor: Centre Hospitalier Intercommunal de Créteil


title: Etude exploratoire de l’effet d’un traitement par acide nicotinique sur l’inflammation du tissu adipeux sous cutané

acronym: NIACINE 4

lead_sponsor: CHU de Toulouse


title: Etude multicentrique randomisée évaluant l’intérêt du Rituximab pour le traitement des glomérulonéphrites extra membraneuses idiopathiques

acronym: GEMRITUX

lead_sponsor: ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP)


title: Comparison between two methods of post-operative analgesia after thoracotomy: epidural administration of sufentanil and levobupivacaine and epidural administration of levobupivacaine associated with intravenous infusion of ketamine (Monocentric, prospective, randomized, double-blind study)

acronym: Sufentanil vs Kétamine

lead_sponsor: Hopital Foch


title: A Phase II, Multicenter, Open-Label Study Of YM155 Plus Docetaxel in Subjects with Stage III (Unresectable) or Stage IV Melanoma

lead_sponsor: Astellas Pharma Global Development, Inc. (APGD)


title: Randomized, Double-blind, Placebo-Controlled Phase 2 Study to Evaluate the Efficacy and Safety of Maralixibat in the Treatment of Subjects with Biliary Atresia after Hepatoportoenterostomy

acronym: EMBARK: Evaluation of Maralixibat in Biliary Atresia Response post Kasai

lead_sponsor: Mirum Pharmaceuticals Inc.


title: A multi-center, double-blind, randomized, placebo-controlled, titration study to investigate the safety, the tolerability and the pharmacodynamic profiles of different doses of RO5073031 in patients with type 2 diabetes mellitus treated with a stable dose of metformin.

lead_sponsor: F. Hoffmann-La Roche Ltd


title: A Phase 3 Study Evaluating Gene Therapy by Transplantation of Autologous CD34+ Stem Cells Transduced Ex Vivo with the LentiGlobin BB305 Lentiviral Vector in Subjects with Sickle Cell Disease.

lead_sponsor: bluebird bio, Inc.


title: Calcipotriol Plus Hydrocortisone Ointment Compared with Tacalcitol Ointment in Patients with Psoriasis Vulgaris on the Face and on the Intertriginous Areas. A phase 3 study comparing an ointment containing calcipotriol 25 mcg/g plus hydrocortisone 10 mg/g with tacalcitol 4 mcg/g ointment and the ointment vehicle alone, all applied once daily in the treatment of psoriasis vulgaris on the face and on the intertriginous areas

lead_sponsor: LEO Pharma A/S


title: A Phase I/II, Open Label, Multi-centre Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of the Tor Kinase Inhibitor AZD8055 Administered Orally to Patients with Advanced Solid Tumours, Lymphomas and Endometrial Carcinoma

lead_sponsor: Astrazeneca AB


title:
A Phase 1b/2 study of derazantinib as monotherapy and combination therapy with paclitaxel, ramucirumab or atezolizumab in patients with HER2-negative gastric adenocarcinoma harboring FGFR genetic aberrations (FIDES-03)

 Étude de phase 1b/2 portant sur le dérazantinib en monothérapie et en traitement d’association avec le paclitaxel, le ramucirumab ou l’atézolizumab chez des patients atteints d’un adénocarcinome gastrique HER2 négatif porteur d’aberrations des gènes FGFR (FIDES-03)

lead_sponsor: Basilea Pharmaceutica International Ltd.


title: A Phase I/II, Double-Blind, Dose-Escalation Study to Evaluate the Safety and Antiviral Activity of IDX184 in Treatment-Naïve Subjects Infected with Genotype 1 Chronic Hepatitis C

lead_sponsor: Idenix Pharmaceuticals, Inc.


title: Multicentre, prospective, assessor-blind, in parallel groups randomised and controlled trial of the efficacy and safety of betamethasone valerate 2.25mg medicated plaster (Betesil®, IBSA-Institut Biochimique S.A.) versus 50μg-0,5mg/g calcipotriol-betamethasone (dipropionate) ointment (Daivobet®/Dovobet®, LEO Pharmaceutical Products), in the treatment of chronic plaque psoriasis.

lead_sponsor: IBSA, Institut Biochimique SA


title: A Phase 1b/2, Open-Label Study Evaluating the Safety and Efficacy of KRT-232 in Patients with p53 Wild Type (p53WT) Merkel Cell Carcinoma (MCC) Who Have Failed Anti-PD-1 or Anti-PD-L1 Immunotherapy, or in Combination with Avelumab in MCC Patients who are Anti-PD-1 or Anti-PD-L1 Treatment Naïve

lead_sponsor: Kartos Therapeutics, Inc.


title: Randomised, double-blind, placebo-controlled, parallel group study to assess the efficacy (bronchodilation) and safety of 4 weeks of once daily treatment of orally inhaled BI 1744 CL (2 µg, 5 µg, 10 µg, 20 µg) delivered by the Respimat® inhaler in patients with asthma

acronym: BI 1744 CL in Asthma

lead_sponsor: Boehringer Ingelheim France


title:
A Phase 2 Open-label, Multicenter, Randomized, Multidrug Platform Study of Neoadjuvant Durvalumab Alone or in Combination with Novel Agents in Subjects with Resectable, Early-stage (I [> 2 cm] to IIIA) Non-small Cell Lung Cancer (NeoCOAST)

 Étude ombrelle de phase 2, multicentrique, randomisée, en ouvert, visant à évaluer le durvalumab en traitement néoadjuvant seul ou en association avec de nouveaux agents chez des patients atteints d’un cancer bronchique non à petites cellules de stade précoce (I [> 2 cm] à IIIA) résécable (NEOCOAST)

acronym: NeoCOAST

lead_sponsor: MedImmune, LLC, a wholly owned subsidiary of AstraZeneca PLC


title: A Phase 1b/2 Trial of AMG 655 in Combination with Panitumumab in Subjects with Metastatic Colorectal Cancer

lead_sponsor: Amgen Inc.


title: A Randomized, Double-blind, Placebo-controlled, Multiple-dose Study to Evaluate the Safety, Tolerability, and Efficacy of AMG 827 in Subjects with Psoriasis

lead_sponsor: Amgen Inc


title:
A phase I/II multi-center study of HDM201 added to chemotherapy in adult subjects with relapsed/refractory (R/R) or newly diagnosed acute myeloid leukemia (AML)

 Etude de phase I/II, multicentrique, évaluant HDM201 associé à un traitement par chimiothérapie chez des patients adultes atteints de leucémie aiguë myéloïde (LAM) en rechute ou réfractaire (R/R) ou nouvellement diagnostiquée

lead_sponsor: Novartis Pharma AG


title: A Phase III Multicenter Open-Label Randomized Trial to Evaluate Efficacy and Safety of FOLFIRINOX (FFX) versus Combination of CPI-613 with modified FOLFIRINOX (mFFX) in Patients with Metastatic Adenocarcinoma of the Pancreas

acronym: PANC003 (also known as “AVENGER 500”)

lead_sponsor: Rafael Pharmaceuticals, Inc


title: Etude de phase III du SU011248 chez les patients atteints d'un cancer épidermoïde de la tête et du cou en situation de rechute locorégionale et/ou métastatique

lead_sponsor: UCL Saint Luc 1200 Bruxelles


title:
A Multicenter, Randomized,  Open-label, Crossover, Phase 2 Study to Evaluate the Safety and Pharmacokinetics of IgPro20  (subcutaneous immunoglobulin, Hizentra®) and IgPro10 (intravenous immunoglobulin, Privigen®) in  Adults with Systemic Sclerosis (SSc).

 Étude de phase II multicentrique, randomisée, menée en ouvert, avec permutation des traitements, visant à évaluer la sécurité d’emploi et la pharmacocinétique de l’IgPro20 (immunoglobuline injectable par voie sous-cutanée, Hizentra®) et de l’IgPro10 (immunoglobuline injectable par voie intraveineuse, Privigen®) chez des patients adultes atteints de sclérodermie systémique (ScS).

lead_sponsor: CSL Behring GmbH


title: A PHASE 1, MULTICENTRE, OPEN-LABEL, DOSE-ESCALATION AND COHORT EXPANSION STUDY OF NIRAPARIB AND DOSTARLIMAB IN PAEDIATRIC PATIENTS WITH RECURRENT OR REFRACTORY SOLID TUMOURS

acronym: Storytime

lead_sponsor: GlaxoSmithKline Research & Development Limited


title: A Multicenter, Open-label Extension Study to Evaluate the Safety, Pharmacodynamics, and Clinical Effects of WVE-120102 in Patients with Huntington’s Disease

lead_sponsor: Wave Life Sciences UK Limited


title: An open label, multi-centre, phase I/IIa study evaluating the safety and clinical activity of neoantigen reactive T cells in patients with advanced non-small cell lung cancer.

acronym: ATX-NS-001 - ATL001 for the Treatment of Non-Small Cell Lung Cancer

lead_sponsor: Achilles Therapeutics Limited


title: A 3-part study to evaluate the efficacy and safety of venglustat in combination with Cerezyme in adult and pediatric patients with Gaucher disease Type 3 (GD3) with open-label long-term treatment

lead_sponsor: Genzyme Corporation


title: A randomized phase II dose-finding study of hexaminolevulinate (HAL) photodynamic therapy (PDT) in patients with low-grade cervical intraepithelial neoplasia (CIN1).

lead_sponsor: Photocure ASA


title:
A Two-cohort, Phase 2 Study of FL-101 as Neoadjuvant Therapy in Patients with Surgically Resectable Non-Small Cell Lung Cancer

 Étude de phase 2 à deux cohortes portant sur FL-101 en traitement néoadjuvant chez des patients atteints d’un cancer bronchique non à petites cellules opérable

acronym: Phase 2 Study of FL-101 in NSCLC

lead_sponsor: Flame Biosciences


title: A Phase I/II Study of Paclitaxel plus Carboplatin and Durvalumab (MEDI4736) with or without Oleclumab (MEDI9447) for Previously Untreated Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer

acronym: SYNERGY trial

lead_sponsor: Institut Jules Bordet


title: Avelumab as neoadjuvant therapy in subjects with urothelial muscle invasive bladder cancers

acronym: AURA

lead_sponsor: Insitut Jules Bordet


title: Neo-adjuvant chemotherapy combined with SBRT to the primary tumour +/- durvalumab (MEDI4736), +/- oleclumab in luminal B breast cancer: a phase ll randomized trial

acronym: neo-checkray


title:
Prospective validation of a predictive model of response to romiplostim in patients with IPSS low or intermediate-1 risk myelodysplastic syndrome (MDS) and thrombocytopenia - the EUROPE-trial

 Validation prospective d’un modèle prédictif de réponse au Romiplostim (Nplate®) chez les patients atteints d’un syndrome myélodysplasique de score IPSS de faible risque ou intermédiaire-1 et de thrombocytopénie – Étude EUROPE

acronym:
Europe

 Europe

lead_sponsor: GMIHO Gesellschaft für Medizinische Innovation - Hämatologie und Onkologie mbH


title: A Phase 3, Randomized, Open-Label Study of Belantamab Mafodotin Administered in Combination with Bortezomib, Lenalidomide and Dexamethasone Versus Bortezomib, Lenalidomide and Dexamethasone Alone in Participants with Newly Diagnosed Multiple Myeloma who are Ineligible for Autologous Stem Cell Transplantation

acronym: Phase 3 Study of Belantamab Mafodotin Plus VRd vs. VRd in Transplant Ineligible Newly Diagnosed MM

lead_sponsor: GlaxoSmithKline Research & Development Ltd


title:
A Phase 1b/3 double-blind, randomized, active-controlled, 3-stage, biomarker adaptive study of tazemetostat or placebo in combination with lenalidomide plus rituximab in subjects with relapsed/refractory follicular lymphoma

 Étude de phase 1b/3 randomisée, en double aveugle, en 3 étapes, avec design adaptatif selon biomarqueur, du tazémétostat ou placebo en association au lénalidomide et rituximab chez des patients atteints d’un lymphome folliculaire en rechute ou réfractaire

lead_sponsor: Epizyme, Inc.


title:
A Phase 3 Study of Adjunctive XEN496 in Pediatric Subjects with KCNQ2 Developmental and Epileptic Encephalopathy

 Étude de phase III évaluant le XEN496 en traitement adjuvant chez des patients pédiatriques atteints d’encéphalopathie épileptique et développementale associée à KCNQ2

acronym: EPIK

lead_sponsor: Xenon Pharmaceuticals Inc.


title: A Phase 2, Multicenter, Double-Blind, Randomized, Stratified, Controlled, Efficacy, Safety and Feasibility Study of rhBMP-2/CPM as an Adjuvant Therapy in Closed Fractures of the Humerus

lead_sponsor: Wyeth Pharmaceuticals Inc.


title: An Open Label Multi-center Study to Assess the Efficacy and Safety of B-Domain Deleted Recombinant Factor VIII (BDDrFVIII, ReFacto AF) in Patients With Hemophilia A Undergoing Elective Major Surgery

lead_sponsor: Wyeth Research Division of Wyeth Pharmaceuticals, Inc. Clinical Research and Development


title: A Phase 1/2 Open-label, Multicenter, Dose Escalation and Dose Expansion Study of the Safety, Tolerability, and Pharmacokinetics of HPN217 in Patients with Relapsed/Refractory Multiple Myeloma

lead_sponsor: Harpoon Therapeutics, Inc.


title: Efficacy and Safety of Hydrochlorothiazide Used as Add-on Therapy in Moderately to Severely Hypertensive Patients not Adequately Controlled by Olmesartan Medoxomil 40 mg Monotherapy

lead_sponsor: DAIICHI SANKYO EUROPE GmbH


title:
Open label, multicentre study, evaluating the safety, tolerability, efficacy, compliance and the acceptability of alkalising treatments at long-term in patients with cystinuria

 Etude multi-centrique, en ouvert, évaluant la sécurité d’emploi, la tolérabilité, l’efficacité, l’observance et l’acceptabilité de traitements alcalinisants à long terme chez des patients présentant une cystinurie.

lead_sponsor: Advicenne


title: RENAL SAFETY EVALUATION AFTER DOTAREM-ENHANCED  MRA COMPARED WITH NON-ENHANCED MRI IN PATIENTS AT HIGH RISK OF DEVELOPING CONTRAST MEDIUM INDUCED NEPHROPATHY.

lead_sponsor: GUERBET


title: Diagnostic value of 18F-choline PET/CT for the detection of systemic prostate cancer disease.

lead_sponsor: CIS bio international, member of IBA group


title: A randomized, open-label, multi-center, comparative trial, to assess the efficacy and safety of pritelivir versus foscarnet for the treatment of acyclovir-resistant mucocutaneous HSV infections in immunocompromised subjects (PRIOH-1)

lead_sponsor: AiCuris Anti-infective Cures GmbH


title:
A Phase 2, Multicenter, Open-Label, Extension Study to Evaluate the Long-Term  Administration of ALN-GO1 in Patients with Primary Hyperoxaluria Type 1

 Étude d'extension de phase II, multicentrique, en ouvert, visant à évaluer l'administration à long terme d'ALN-GO1 chez des patients atteints d'hyperoxalurie primitive de type 1

lead_sponsor: Alnylam Pharmaceuticals, Inc.


title: A randomized, observer blind, multinational phase III study to evaluate the safety and efficacy of a nanoemulsion gel formulation BF-200 ALA, in comparison with Metvix® and placebo, for the treatment of actinic keratosis with photodynamic therapy

lead_sponsor: Biofrontera Bioscience GmbH


title: Phase III multicentric study evaluating the efficacy and safety of sirolimus in Vascular Anomalies that are refractory to standard care

acronym: VASE

lead_sponsor: Cliniques Universitaires Saint-Luc (CUSL)


title: Comparison of the safety and efficacy of volinanserin and lormetazepam in the treatment of insomnia characterized by sleep maintenance difficulties. A 4 week, randomized, double-blind, double-dummy, comparative, parallel-group study.

acronym: REST

lead_sponsor: sanofi-aventis recherche & développement


title: A double-blind, randomized, placebo-controlled, study evaluating the safety and activity of four escalating single doses of AVE0657 in congestive heart failure patients presenting as Cheyne-Stokes Breathing Syndrome


title: A MULTICENTER OPEN LABEL PHASE II STUDY OF THE EFFICACY AND SAFETY OF AMG 479, A FULLY HUMAN MONOCLONAL ANTIBODY AGAINST INSULIN-LIKE GROWTH FACTOR TYPE 1 RECEPTOR (IGF-1R) AS SECOND LINE THERAPY IN PATIENTS WITH RECURRENT PLATINUMSENSITIVE OVARIAN CANCER

lead_sponsor: Cancer International research Group


title: A PHASE 2, 12 WEEK, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL GROUP, PROOF OF CONCEPT STUDY EVALUATING THE EFFICACY AND SAFETY OF PD 0299685 FOR THE TREATMENT OF SYMPTOMS ASSOCIATED WITH INTERSTITIAL CYSTITIS/PAINFUL BLADDER SYNDROME.

lead_sponsor: Pfizer Ltd;Ramsgate Road,Sandwich,Kent CT13 9NJ


title: A randomised, double-blind, placebo-controlled, multi-national, multi-centre, Phase III paediatric study of the efficacy and safety of 300 IR sublingual immunotherapy (SLIT) administered as allergen-based tablets once daily to children suffering from grass pollen rhinoconjunctivitis

lead_sponsor: Stallergenes S.A.


title: An open-label, randomized, controlled Phase-II trial evaluating the efficacy and safety of EndoTAG-1 in triple receptor negative breast cancer patients

lead_sponsor: MediGene AG


title: A MULTICENTER, OPEN-LABEL PHARMACOKINETIC, PHARMACODYNAMIC, CLINICAL SYMPTOMS, AND SAFETY STUDY OF PANTOPRAZOLE DELAYED-RELEASED GRANULES ADMINISTERED AS A SUSPENSION IN NEONATES AND PRETERM INFANTS WITH A CLINICAL DIAGNOSIS OF GASTROESOPHAGEAL REFLUX DISEASE

lead_sponsor: Wyeth Research, Clinical Research and Development, Division of Wyeth Pharmaceuticals Inc.


title: A phase III randomized study evaluating surgery of residual disease in patients with metastatic gastro-intestinal stromal tumor responding to Imatinib mesylate.

lead_sponsor: European Organization for Research and Treatment of Cancer


title: A Double-Masked, Placebo-Controlled, Parallel Group, Multi-Centre, Dose-Ranging Study to Assess the Efficacy and Safety of LX211 as Therapy in Subjects with Active Sight Threatening, Non-Infectious Anterior Uveitis.

lead_sponsor: Lux Biosciences GmbH


title: A MULTI-CENTER, DOUBLE-BLIND, RANDOMIZED, PARALLEL-GROUP STUDY OF THE EFFICACY AND SAFETY OF TWO LENALIDOMIDE DOSE REGIMENS IN SUBJECTS WITH RELAPSED OR REFRACTORY B-CELL CHRONIC LYMPHOCYTIC LEUKEMIA

lead_sponsor: Celgene Corporation


title: A Randomised Phase III Trial Comparing Concurrent Chemoradiation and Adjuvant Chemotherapy with Pelvic Radiation Alone in High Risk and Advanced Stage Endometrial Carcinoma

acronym: FEDEGYN 01/0902  - PORTEC 3

lead_sponsor: Leiden University Medical Centre


title:
A Comparative Study of Chronic Hepatitis B Subjects Treated with Entecavir Plus Tenofovir Combination Therapy vs Entecavir Monotherapy in Adults who are Treatment-Naïve to Nucleosides and Nucleotides: The BE-LOW Study.
 Revised Protocol 01, incorporating protocol amendment 02 (Version 2.0, Date 22-Jan-07).

acronym: The BE-LOW Study

lead_sponsor: Bristol-Myers Squibb International Corporation


title: A non-randomized, open-label study to characterize the pharmacokinetics of Glivec/Gleevec® (imatinib mesylate) in pediatric (age range 1 to less than 4 years) patients with chronic myeloid leukemia (CML) or Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL)

lead_sponsor: Novartis Pharma Service AG


title: A Phase II, Double-blind, Placebo-Controlled, Randomised Study to Assess the Efficacy and Safety of ZD4054 in Combination with Pemetrexed (Alimta®) vs. Pemetrexed Alone in Patients with Non-small Cell Lung Cancer who Have Failed One Prior Platinum-based Chemotherapy Regimen.

lead_sponsor: AstraZeneca AB


title: A randomised double-blind placebo-controlled phase IIa study of orally administered BGC20-0134 in patients with relapsing-remitting multiple sclerosis (RRMS)

lead_sponsor: BTG International Ltd


title: Efficacy and safety of 2 mg/day M100907 on Sleep Maintenance Insomnia: a 6-week, multicenter, randomized, double-blind, placebo-controlled Polysomnographic study

acronym: Nocturne 907 (NPSG study of M100907)


title: Eltrombopag for the treatment of thrombocytopenia due to low- and intermediate risk myelodysplastic syndromes.

lead_sponsor: ASSOCIAZIONE QOL-ONE


title: A phase II study of CP-4126 in patients with advanced pancreatic cancer

lead_sponsor: Clavis Pharma ASA


title: A Phase III, Randomized, Double-Blind, Placebo-Controlled Study of AST-120 for Prevention of Chronic Kidney Disease Progression in Patients with Moderate to Severe Chronic Kidney Disease

lead_sponsor: Kureha Corporation


title: An open-label extension to a 52-week, multi-center, randomized, double-blind, placebo-controlled, parallel group study in patients with mild Alzheimer’s Disease (AD) to investigate the safety and tolerability of repeated subcutaneous injections of CAD106

acronym: Not applicable.

lead_sponsor: Novartis Pharma Services AG


title: Multicentre, controlled, randomized, investigator-blinded, comparative study of oral  Mesalazine 4g per day Once daily versus 4g per day in Two divided doses  in patients with active Ulcerative colitiS

acronym: MOTUS

lead_sponsor: Ferring SAS


title:
A Phase 2, Multi-Center, Randomized, Open-Label, Repeat Dose, Dose-Comparison Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of Recombinant Human Acid Sphingomyelinase in Patients With Acid Sphingomyelinase Deficiency

 Etude de Phase II, multicentrique, randomisée, en ouvert, de doses répétées, de comparaison de doses, visant à évaluer la tolérance, l’efficacité et la pharmacocinétique de la sphingomyelinase acide humaine recombinante chez des patients avec un déficit en sphingomyelinase acide

lead_sponsor: Genzyme Corporation


title: A randomized, prospective, double-blind, placebo-controlled, group sequential multicenter study to assess efficacy, safety, and tolerability of the pediatric formulation of bosentan in children with pulmonary arterial hypertension

acronym: FUTURE 5

lead_sponsor: Actelion pharmaceuticals Ltd


title: A randomised, double-blind study evaluating the safety, tolerability and clinical outcome of Neoven compared to Vaminolact in premature ELBW infants

lead_sponsor: Fresenius Kabi Deutschland GmbH


title: An Open-Label, Pharmacokinetic and Safety Study of Travoprost Ophthalmic Solution, 0.004% in Pediatric Glaucoma or Ocular Hypertension Patients

acronym: Pharmacokinetic and Safety Study of Travoprost 0.004% in Pediatric Glaucoma Patients

lead_sponsor: Alcon Research Ltd


title: A Phase IIa, randomized, double-blind, placebo-controlled, multi-center study to evaluate the safety, tolerability, and effects of AZP-531, an Unacylated Ghrelin analog, on food-related behavior in patients with Prader-Willi Syndrome

lead_sponsor: Alize Pharma


title:
A Phase I/II, Multicenter, Open-label, Clinical Trial of Intratumoral/Intralesional Administration of RGT100 in Subjects with Advanced or Recurrent Tumors

 Etude Clinique de phase I/II, multicentrique et en ouvert, évaluant l'administration intratumorale/lésionnelle de RGT100 chez des patients atteints de tumeurs avancées ou récidivantes.

acronym: A Phase I/II trial of intralesional administration of RGT100

lead_sponsor: Rigontec GmbH


title: A phase Ib/II multi-center, open label, dose escalation study of WNT974, LGX818 and cetuximab in patients with BRAFV600-mutant KRAS wild-type metastatic colorectal cancer harboring Wnt pathway mutations

lead_sponsor: Array BioPharma Inc.


title:
AN OPEN-LABEL EXPLORATORY STUDY OF UCB5857 IN SUBJECTS WITH ACTIVATED PHOSPHOINOSITIDE 3 KINASE (PI3K) DELTA SYNDROME (APDS)

 ÉTUDE EXPLORATOIRE OUVERTE ÉVALUANT L’UCB5857 CHEZ DES PATIENTS PRÉSENTANT UN SYNDROME DE PHOSPHO-INOSITIDE-3-KINASE (PI3K) DELTA ACTIVÉE (SYNDROME APDS)

lead_sponsor: UCB Celltech, UK Registered Branch of UCB Pharma SA


title: Colchicine Cardiovascular Outcomes Trial (COLCOT)

acronym: COLCOT

lead_sponsor: Montreal Heart Institute


title: A Phase II randomised, placebo-controlled trial of vedolizumab with or without therapeutic HIV MVA vaccine in individuals who started antiretrovirals during primary or chronic infection

lead_sponsor: Inserm-ANRS


title: A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multi-Center Trial to Evaluate the Efficacy and Safety of a Single Treatment of DaxibotulinumtoxinA for Injection in Adults with Isolated Cervical Dystonia (ASPEN-1)

lead_sponsor: Revance Therapeutics Inc


title: OPEN-LABEL STUDY TO INVESTIGATE THE PHARMACOKINETICS AND SAFETY OF TASIMELTEON IN TOTALLY BLIND CHILDREN AND ADOLESCENTS WITH NON-24-HOUR SLEEP- WAKE DISORDER

lead_sponsor: Vanda Pharmaceuitcals Inc.


title: A Phase II Clinical Trial of Pembrolizumab (MK-3475) as Monotherapy for Metastatic Triple-Negative Breast Cancer (mTNBC) – (KEYNOTE-086)

acronym: A Phase II Study of Pembrolizumab in Subjects with Triple-Negative Breast Cancer

lead_sponsor: Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.


title: A Double-Masked, Placebo-Controlled, Parallel-Group, Multi-Center, Dose-Ranging Study to Assess the Efficacy and Safety of LX211 as Therapy in Subjects with Active Sight Threatening, Non-Infectious Intermediate-, Anterior and Intermediate-, Posterior-, or Pan-Uveitis.

lead_sponsor: Lux Biosciences GmbH


title: Multicenter, randomized, open label study evaluating an anti Insulin-like Growth Factor-1 Receptor (IGF-1R/CD221) monoclonal antibody, AVE1642, administered every 4 weeks in combination with fulvestrant (Faslodex®) in postmenopausal patients with advanced hormono-dependent breast cancer

lead_sponsor: sanofi-aventis recherche et développement


title: Efficacy and safety of the fixed oral low-dose perindopril arginine 3.5 mg/amlodipine 2.5 mg combination compared with each component (perindopril arginine 3.5 mg and amlodipine 2.5 mg) and with perindopril arginine 5 mg and amlodipine 5 mg. Randomized, double-blind, placebo-controlled study over 8 weeks in hypertensive patients.

lead_sponsor: Institut de Recherches Internationales Servier


title: An open-label, randomised, comparative, multi-centre study of the immunogenicity and safety of a 2-dose regimen of ProQuad® manufactured with rHA administered to healthy children from 9 months of age

lead_sponsor: Sanofi Pasteur MSD SNC


title: A Multi-Center, Placebo-Controlled, Double-Blind Trial To Examine the Safety and Efficacy of ACP-103 in the Treatment of Psychosis in Parkinson's Disease

lead_sponsor: Acadia Pharmaceuticals Inc


title: A phase 3, open-label 96-week extension study of the safety of apricitabine in treatment-experienced HIV-1 infected patients who have completed protocol AVX-301 or AVX-302 or who have met the criteria for open-label access to ATC because of virologic failure/lack of response.

lead_sponsor: Avexa Limited


title: A Phase IIa randomized, partially blinded trial of telaprevir (VX-950) in treatment-naïve subjects with chronic genotype 2 or 3 hepatitis C infection

lead_sponsor: Tibotec BVBA


title:
A Randomized, Double-Blind, Parallel, Three Arm, Multicenter, Phase II Trial Evaluating the Efficacy and Safety of Ipilimumab (BMS-734016) in Combination with Taxol®/Paraplatin® (Paclitaxel/Carboplatin) Compared to Taxol®/Paraplatin® Alone in Previously Untreated Subjects with Lung Cancer
 + Pharmacogenetics Blood Sample Amendment Number 01 - Site Specific, version 2.0 dated 20-Jul-07

lead_sponsor: Bristol-Myers Squibb International Corporation


title:
A Randomized, Multi-Dose, Open-Label, Phase II Study of BMS-663513 as a Second-Line Monotherapy in Subjects with Previously Treated Unresectable Stage III or Stage IV Melanoma.
 And Pharmacogenetics Blood Sample Amendment Number 01 - Site Specific (Version 1.0, Date 26-Nov-2007).


title: A Worldwide, Double-Blind, Randomized, Placebo-Controlled Study of MK-0524A 2g Coadministered with Intensive LDL-C Lowering Therapy Compared to Intensive LDL-C Lowering Therapy Alone on Carotid Artery Intima Medial Thickness (cIMT) in Patients With Heterozygous Familial Hypercholesterolemia (HeFH).

acronym: Carotid IMT Study

lead_sponsor: Laboratoires Merck Sharp & Dohme - Chibret


title: An Open-Label Evaluation of Safety of the IONSYS™ System [Fentanyl Iontophoretic Transdermal System (40 µg)] for Management of Acute Post- Operative Pain in Pediatric Patients

lead_sponsor: Janssen Cilag International N.V.,


title: A Double-Blind, Randomized, Placebo-Controlled Multicenter Study Evaluating the Efficacy and Safety of two doses of Satavaptan (SR121463B) Versus Placebo in Patients with Dilutional Hyponatremia due to the Syndrome of Inappropriate Antidiuretic Hormone Secretion (SIADH)

acronym: AQUARIST I


title: A Multicenter, Randomized, Double-Blind, Placebo-Controlled, 12-Week Study to Evaluate the Efficacy and Safety of Extended Release (ER) Niacin/Laropiprant When Added to Ongoing Lipid-Modifying Therapy in Dyslipidemic Patients.


title: A Phase 4, 8-Week, Double-Blind, Randomized, Placebo-Controlled Study Evaluating the Efficacy of Duloxetine 60 mg Once Daily in Outpatients with Major Depressive Disorder and Associated Painful Physical Symptoms

acronym: Etude HMGR

lead_sponsor: Eli Lilly and Company


title: A phase I-II, randomized, observer-blind, placebo-controlled, dose escalation study to evaluate the safety and immune responses of various doses of Neovacs’ IFNα-Kinoid in adult patients with Systemic Lupus Erythematosus.

acronym: IFN-Kinoid in Systemic Lupus Erythematosus

lead_sponsor: Neovacs SA


title:
A prospective, open label, multicenter, efficacy and safety study of several infusions of Promethera HepaStem in Urea Cycle Disorders pediatric patients

 Etude clinique prospective, ouverte, multicentrique visant à évaluer l’efficacité et la sécurité de plusieurs infusions d'HepaStem chez des patients pédiatriques atteints d’un désordre du cycle de l’urée

lead_sponsor: Promethera Biosciences


title: A Phase IIa, Multicenter, Randomized, Double-Blind, Placebo-Controlled Clinical Trial of MK-0941 in Patients with Type 2 Diabetes Mellitus with Inadequate Glycemic Control on Insulin

lead_sponsor: Laboratoires MSD-Chibret


title: Phase II Study of Dasatinib (BMS-354825) for Advanced ‘Triple-negative’ Breast Cancer + Pharmacogenetics Blood Sample Amendment Number 01 - Site Specific (version 2.0 dated 16-Aug-06) + Pharmacogenomics Tissue Sample Amendment Number 02 - Site Specific - (version 1.0 dated 16-Aug-06)


title: An open-label randomized phase II trial of belinostat (PXD101) in combination with carboplatin and paclitaxel (BelCaP) compared to carboplatin and paclitaxel in patients with previously untreated carcinoma of unknown primary

acronym: BelCaP in CUP

lead_sponsor: TopoTarget A/S


title: A  Phase 2/3, Double-Blind, Randomized, Placebo-Controlled, Multi-center, International Study to Evaluate the Efficacy and Safety of Oxabact(TM) to Reduce Urinary Oxalate in Subjects with Primary Hyperoxaluria.

acronym: Study to see if Oxabact reduces urinary oxalate, the Phoenix study

lead_sponsor: OxThera Inc.


title: A phase II, open label multicenter trial of panobinostat (LBH589) monotherapy in women with HER2 negative locally recurrent or metastatic breast cancer

lead_sponsor: Cancer International Research Group


title: A 54 week, randomized, double-blind, parallel-group, multicenter study evaluating the long-term gastrointestinal (GI) safety and tolerability of aliskiren (300 mg) compared to ramipril (10 mg) in patients with essential hypertension

lead_sponsor: Novartis Pharma Services AG


title: A Randomized, Rater-Blinded Study to Explore the Effect of  Mefloquine in Subjects with Progressive Multifocal Leukoencephalopathy (PML)

lead_sponsor: Biogen Idec Ltd


title: An Open-label, Randomized Study of Subcutaneous and Intravenous VELCADE® in Subjects With Previously Treated Multiple Myeloma

lead_sponsor: Janssen-Cilag International NV (JCI)


title: A Randomized Phase 2 Study of Ixabepilone Plus Carboplatin and Paclitaxel Plus Carboplatin in Subjects With Advanced Non-Small Cell Lung Cancer


title: “A randomised, double-blind, placebo-controlled, parallel-group study of the efficacy and safety of two doses of ketoprofen (as lysinate) lozenges (6.25mg and 12.5mg ) in patients with sore throat”

acronym: KRYSTAL

lead_sponsor: SANOFI-AVENTIS GROUPE


title: A multi-center, double-masked study of the safety and efficacy of Travoprost APS compared to TRAVATAN in patients with open-angle glaucoma or ocular hypertension.

acronym: Efficacy study of Travoprost APS versus TRAVATAN

lead_sponsor: Alcon Research, Ltd.


title: A Study To Evaluate The Safety And Efficacy Of IPX066 In Advanced Parkinson’s Disease

lead_sponsor: Impax Laboratories, Inc.


title: A Phase II Study of Pembrolizumab (MK-3475) as Monotherapy in Subjects with Previously Treated Locally Advanced Unresectable or Metastatic (Stage IV) Mismatched Repair Deficient or Microsatellite Instability-High Colorectal Carcinoma (KEYNOTE-164)

acronym: Phase II Study of Pembrolizumab in Subjects with MMRd or MSI-H CRC

lead_sponsor: Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.


title: A phase II, multinational, multicentre, double blind, double dummy, randomised, 5-way cross-over, placebo and active controlled clinical study to test the non-inferiority of a single dose of CHF 1535 (fixed combination of beclomethasone dipropionate 100 µg plus formoterol fumarate 6 µg dry powder) via NEXT™ DPI 1 or 4 inhalations versus CHF 1535 (beclomethasone dipropionate 100 µg plus formoterol fumarate 6 µg) pMDI with HFA-134a propellant 1 or 4 puffs on FEV1 AUC0-12h in partly controlled adult asthmatic patients

lead_sponsor: Chiesi Farmaceutici S.p.A.


title:
Phase II Study of Dasatinib (BMS-354825) for Advanced Estrogen/Progesterone Receptor-Positive or Her2/neu-Positive Breast Cancer
 + Pharmacogenetics Blood Sample Amendment Number 01 - Site Specific (version 1.0 dated 16-Aug-06) + Pharmacogenomics Tissue Sample Amendment Number 02 - Site Specific - (version 1.0 dated 16-Aug-06)

lead_sponsor: Bristol-Myers Squibb International Corporation


title: Clinical study to investigate the efficacy, the safety and immunogenicity of Wilate in children <6 years of age with inherited von Willebrand disease (VWD)

lead_sponsor: OCTAPHARMA AG


title: A Multicentre, Double-Blind, Placebo-Controlled, Randomized Study of Etanercept in the Treatment of Adults Patients with Active, Severe and Advanced Axial Ankylosing Spondylitis

lead_sponsor: Wyeth Pharmaceuticals France


title: Clinical study to evaluate the efficacity and safety of octagam®10% in idiopathic thrombocytopenic purpura in adults

lead_sponsor: Octapharma AG


title: A RANDOMIZED, DOUBLE BLIND, TWO ARM, PARALLEL, PLACEBO CONTROLLED STUDY OF RIMONABANT 20MG EFFECT ON HIGH DENSITY LIPOPROTEIN KINETICS IN PATIENTS WITH ABDOMINAL OBESITY AND ADDITIONAL CARDIOMETABOLIC RISK FACTORS

acronym: HDL TURNOVER

lead_sponsor: sanofi aventis Groupe


title: A 26-week, multinational, multi-centre, open-labelled, two-arm, parallel, randomised, treat-to-target trial comparing efficacy and safety of soluble insulin analogue combination (SIAC) once daily plus meal-time insulin aspart for the remaining meals vs. basal-bolus treatment with insulin detemir plus meal-time insulin aspart in subjects with type 1 diabetes

lead_sponsor: Novo Nordisk A/S


title: An open, randomised, parallel group, multicentre study to compare the efficacy and safety of FlutiForm pMDI vs Seretide pMDI in paediatric subjects with mild to moderate persistent, reversible asthma.

lead_sponsor: Mundipharma Research Ltd.


title: A MULTICENTER, OPEN LABEL SAFETY STUDY OF 2 DOSES OF PANTOPRAZOLE SODIUM ENTERIC-COATED SPHEROID SUSPENSION IN INFANTS AGED LESS THAN 12 MONTHS WITH PRESUMED GERD

lead_sponsor: Wyeth Research Division of Wyeth Pharmaceuticals Inc, Clinical Research and Development


title: A Phase II Study of PHA-739358 in Patients with Metastatic Hormone Refractory Prostate Cancer.

acronym: not available

lead_sponsor: Nerviano Medical Sciences S.r.l.


title: A double-blind, double-dummy, randomized, parallel groups study to assess the Efficacy, Safety and Tolerability of switching patients with early Parkinson’s disease (PD) from Pramipexole IR to Pramipexole ER or Pramipexole IR.

lead_sponsor: BOEHRINGER INGELHEIM


title: Randomized, double-blind, placebo-controlled add-on trial of the safety and efficacy of RO4917838 in outpatients on olanzapine, quetiapine, risperidone or paliperidone with prominent negative or disorganized thought symptoms

lead_sponsor: F.Hoffmann-La Roche Ltd


title: A multicenter, double-blind, randomized, placebo-controlled study to evaluate the efficacy, safety and tolerability of AVE5530 when added to ongoing stable statin therapy at high doses in patients with severe primary hypercholesterolemia

lead_sponsor: Sanofi-Aventis Recherche & Développement


title: A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, COMPARATIVE STUDY OF THE SAFETY AND EFFICACY OF 2 DOSES OF TIGECYCLINE VERSUS IMIPENEM/CILASTATIN FOR THE TREATMENT OF SUBJECTS WITH HOSPITAL-ACQUIRED PNEUMONIA

lead_sponsor: Wyeth Research Division of Wyeth Pharmaceuticals Inc., Clinical Research and Development


title: A PHASE 2 MULTICENTER, RANDOMIZED, DOUBLE BLIND, PLACEBO-CONTROLLED STUDY OF THE SAFETY, TOLERABILITY, AND PHARMACOKINETICS OF MULTIPLE DOSES OF PF-04360365 IN PATIENTS WITH MILD TO MODERATE ALZHEIMER’S DISEASE.

lead_sponsor: Pfizer Inc., 235 East 42nd Street, New York, NY 10017


title: PHASE I-II STUDY OF VINBLASTINE IN COMBINATION WITH NILOTINIB IN CHILDREN, ADOLESCENTS, AND YOUNG ADULTS WITH REFRACTORY OR RECURRENT LOW-GRADE GLIOMA

acronym: Vinilo

lead_sponsor: Institut de cancérologie Gustave Roussy


title: A double blind, randomised, placebo controlled, parallel group study of Sativex® when added to the existing treatment regimen, in the relief of central neuropathic pain in subjects with multiple sclerosis.

lead_sponsor: GW Pharma Ltd


title: A 2-YEAR, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 3 STUDY TO EVALUATE THE LONG-TERM EFFICACY AND SAFETY OF CP-945,598 IN THE TREATMENT OF OBESE SUBJECTS

lead_sponsor: Pfizer Inc.


title: A randomized, open-label, multi-center study of larotaxel at 90mg/m² or docetaxel every 3 weeks, alone or in combination with trastuzumab according to Her2neu status, administered after a combination regimen of anthracycline and cyclophosphamide as pre-operative therapy in patients with high risk localized breast cancer

acronym: SATIN

lead_sponsor: sanofi-aventis recherche & developpement


title: A Phase II, multicentre, double-blind, randomized, dose range finding placebo controlled study of Rifaximin- EIR tablet: clinical effectiveness and tolerability in the treatment of moderate, active Crohn’s disease

lead_sponsor: Alfa Wassermann S.p.A.


title: A multicenter, double-blind, parallel-group, placebo-controlled study of the effect on cognitive performance and safety/tolerability of SSR180711C, at the doses of 2, 8 and 20 mg/d for 4 weeks, using donepezil as calibrator, in patients with mild Alzheimer's Disease.

lead_sponsor: sanofi-aventis recherche & développement


title: A MULTICENTER, RANDOMIZED, OPEN LABEL, SINGLE AND MULTIPLE DOSE STUDY OF THE PHARMACOKINETICS AND PHARMACODYNAMICS OF 2 DOSE LEVELS OF  PANTOPRAZOLE SODIUM ENTERIC-COATED SPHEROID SUSPENSION IN INFANTS AGED 1 THROUGH 11 MONTHS WITH PRESUMED GERD.


title: A double-blind, randomized, placebo-controlled, study of the safety and activity of four escalating single doses of AVE0657 in patients suffering from Obstructive Sleep Apnea Hypopnea Syndrome


title: A 76-week prospective, open-label, multicenter study to evaluate the long-term effect of Exelon® capsule and transdermal patch on worsening of the underlying motor symptoms of PD in patients with mild to moderately severe dementia associated with Parkinson’s disease (PDD).

lead_sponsor: Novartis Pharma AG


title: A multicenter, Investigator-Masked, Parallel Group, Randomized, Study of the Efficacy and Safety of Indomethacin 0.1% Eyedrops Compared with Ketorolac 0.5% Eyedrops in the Ocular Inflammation After Cataract Surgery.

lead_sponsor: Bausch&Lomb Dr Gerhard Mann chem.-Fabrik GmbH


title: Multicenter, randomized, double-blind, placebo-controlled, Phase IIa study to evaluate the efficacy, safety, and tolerability of ACT-128800, an S1P1 receptor agonist, administered for 6 weeks to subjects with moderate to severe chronic plaque psoriasis

lead_sponsor: Actelion Pharmaceuticals Ltd


title: A randomised controlled parallel group open-label study to evaluate the efficacy and safety of intravenous ferric carboxymaltose versus no treatment in anaemic subjects with multiple myeloma and iron-restricted erythropoiesis receiving chemotherapy

lead_sponsor: Vifor Pharma Inc.


title: A 52 week randomised, controlled, open label, multicentre, multinational, parallel, treat-to-target trial comparing efficacy and safety of SIBA and insulin glargine both administered once daily in a basal-bolus regimen with insulin aspart as mealtime insulin in subjects with type 1 diabetes

lead_sponsor: Novo Nordisk A/S


title: A 6-Month, Single-Masked, Multicenter, Randomized, Controlled Study to Assess the Safety and Efficacy of 700 μg Dexamethasone Posterior Segment Drug Delivery System Applicator System as Adjunctive Therapy to Lucentis® Compared with Lucentis® Alone in the Treatment of Patients with Choroidal Neovascularization Secondary to Age-Related Macular Degeneration

lead_sponsor: Allergan Limited


title: Xenetix 350 : comparative assessment of image quality for coronary CT angiography

acronym: X-ACT study

lead_sponsor: GUERBET


title: A Double-Blind, Placebo-Controlled Study on the Effects of MIN-102 on Biochemical, Imaging, Neurophysiological, and Clinical Markers in Patients with Friedreich’s Ataxia

lead_sponsor: Minoryx Therapeutics BE, SA


title: A Multicenter, Placebo-Controlled, Double-Blind, Randomized, Parallel-Group, Phase 2b Study to Evaluate the Efficacy and Safety of Ecopipam Tablets in Children and Adolescent Subjects with Tourette’s Syndrome

acronym: Diamond

lead_sponsor: Emalex Biosciences, Inc.


title: An eight-week, double-blind, placebo-controlled study to evaluate the efficacy, safety, and tolerability of saredutant 100 mg once daily in combination with escitalopram 10 mg once daily in patients with major depressive disorder


title: Essai multicentrique prospectif randomisé en double aveugle et en groupes parallèles, destiné à évaluer les effets de doses ascendantes de BF2.649 et de BF2.649 combiné à du modafinil dans le traitement de la cataplexie chez des patients narcoleptiques

acronym: Harmony II

lead_sponsor: Bioprojet


title: A PHASE 2 EFFICACY AND SAFETY STUDY OF SU011248 IN PATIENTS WITH NON-SMALL CELL LUNG CANCER AND BRAIN METASTASES

lead_sponsor: Pfizer Inc. - 235 East 42nd Street - New York - 10017


title:
A Multicenter, Double-Blind, Placebo-Controlled, Parallel Group, Randomized, Phase 2 Trial to Evaluate the Glycemic Efficacy, Renal Safety, Pharmacokinetics, and Pharmacodynamics of Dapagliflozin in Subjects with Type 2 Diabetes Mellitus and Moderate Renal Impairment Who Have Inadequate Glycemic Control.
 Revised Protocol 01, incorporating Protocol Amendment 02 (Version 1.0, Date 10-Apr-2008). And Pharmacogenetics Blood Sample Amendment 01 - Site specific (Version 2.0, Date 10-Mar-2008).

lead_sponsor: Bristol-Myers Squibb International Corporation


title: A randomized, double-blind, placebo-controlled, 2-arm parallel-group, multicenter study with a 24-week main treatment period and an extension assessing the efficacy and safety of AVE0010 on top of pioglitazone in patients with type 2 diabetes not adequately controlled with pioglitazone.

acronym: GETGOAL-P

lead_sponsor: Sanofi-Aventis Recherche & Développement


title: L'Erythropoïetine dans les traumatismes crâniens (EPO-TBI)

acronym: EPO-TBI

lead_sponsor: Monash University


title: An open-label, multicenter phase II extension of study 28063 (ATAMS) to obtain long-term follow-up data in patients with relapsing multiple sclerosis treated with atacicept for up to 5 years (ATAMS-Extension)

acronym: Atacicept 28063 (RMS) extension study

lead_sponsor: Merck Serono International


title: A phase Ib/II study of the ALK inhibitor ceritinib in combination with the CDK4/6 inhibitor LEE011 in patients with ALK-positive Non-small Cell Lung Cancer

lead_sponsor: Novartis Pharma Services AG


title: Randomized, Non-comparative Neoadjuvant Phase II Study in Patients with ER+/HER2- Breast Cancer >= 2 cm with Safety Run-in, Assessing Nivolumab + Abemaciclib or Palbociclib + Anastrozole

acronym: CheckMate 7A8: CHECKpoint pathway and nivoluMAb clinical Trial Evaluation 7A8


title:
A Phase 1/2 Study of FPA008, an anti-CSF1 Receptor Antibody, in Patients with Pigmented Villonodular Synovitis (PVNS)/ Diffuse Type Tenosynovial Giant Cell Tumor (dt-TGCT)

 Étude de phase 1/2 sur le FPA008, un anticorps anti-récepteur du CSF1 chez les patients atteints de synovite villonodulaire pigmentée (SVNP)/tumeur ténosynoviale à cellules géantes de type diffus (TTCG-td)

acronym: Phase 1/2 of FPA008 in PVNS/dt-TGCT

lead_sponsor: Five Prime Therapeutics, Inc.


title:
A Multicenter, Phase 2 Study of Tesetaxel plus Three Different PD-(L)1 Inhibitors in Patients with Triple-Negative, Locally Advanced or Metastatic Breast Cancer and Tesetaxel Monotherapy in Elderly Patients with HER2 Negative, Locally Advanced or Metastatic Breast Cancer

 Étude multicentrique de phase 2 portant sur le tésétaxel et trois inhibiteurs différents du PD-(L)1 chez des patients atteints d’un cancer du sein triple-négatif, localement avancé ou métastatique et sur le tésétaxel en monothérapie chez des patients âgés présentant un cancer du sein HER2 négatif, localement avancé ou métastatique

lead_sponsor: Odonate Therapeutics, Inc.


title: A Placebo-Controlled, Single-Blind, Single-Center Phase 1 Study in Normal Healthy Volunteers and Open-Label Multi Center Study in Patients with Primary Hyperoxaluria to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Ascending Doses of DCR PHXC Solution for Injection (subcutaneous use)

acronym: 2-part study of DCR-PHXC in NHV and PH patients

lead_sponsor: Dicerna Pharmaceuticals Inc


title: Tadalafil 5 mg Once a Day Compared to Placebo in Improving Erectile Dysfunction  and Sexual Quality of Life

acronym: LVGH

lead_sponsor: Lilly ICOS LLC


title: A Phase I /II Dose Escalation and Cohort Expansion Study of the Safety, Tolerability and Efficacy of Anti-KIR (Lirilumab) Administered in Combination with Anti-PD-1 (Nivolumab) in Advanced Refractory Solid Tumors


title:
A Randomised, Double-Blind, Placebo-Controlled, Phase II Study to Assess the Efficacy and Safety of Orally Administered DS102 in Patients with Severe Acute Decompensated Alcoholic Hepatitis.

 Etude de phase II, randomisée, en double-aveugle, contrôlée contre placebo, évaluant l’efficacité et la tolérance du DS102 administré par voie orale chez des patients atteints d’hépatite alcoolique aiguë sévère

lead_sponsor: Afimmune


title: An Exploratory, Multi-center, Open-Label, Single-Arm study to evaluate the Discontinuation Effect of Clopidogrel After Drug Eluting Stent (DECADES) on Inflammatory and Platelet Activation Markers in Subjects Who Are Receiving Low Dose Acetylsalicylic Acid (ASA).

acronym: DECADES

lead_sponsor: Bristol Myers Squibb International Corporation


title:
A Phase 3, Randomized, Double-Blind, Vehicle-Controlled Study to Evaluate the Efficacy and Safety of Maintenance Treatment and Flare Reduction with Crisaborole Ointment, 2%, Once Daily Over 52 Weeks in Pediatric and Adult Participants (Ages 2 Years and Older) with Mild-to-Moderate Atopic Dermatitis, who Responded to Twice Daily Crisaborole Ointment, 2%, Treatment

 Étude de phase 3, randomisée, en double aveugle, contrôlée par placébo, évaluant l’efficacité et la tolérance du traitement d’entretien et de la réduction des poussées par crisaborole, pommade à 2 %, une fois par jour pendant 52 semaines chez l’adulte et l’enfant (à partir de 2 ans) présentant une dermatite atopique légère à modérée, ayant répondu au traitement deux fois par jour par crisaborole, pommade à 2 %

acronym: CrisADe Control

lead_sponsor: Pfizer Inc., 235 East 42nd Street, New York, NY 10017


title: A Phase Ib/II, open-label study of the safety, tolerability, and efficacy of trastuzumab-MCC-DM1 in combination with pertuzumab administered intravenously to patients with HER2-positive locally advanced or metastatic breast cancer who have progressed while receiving prior therapy

lead_sponsor: F. Hoffmann-la Roche Ltd


title: A Multicentre, Double-blind, Placebo-Controlled, Parallel Group Study of the Effect of Oral Etamsylate (Dicynone®) in Patients with Menorrhagia

acronym: Effects of Oral Etamsylate in Patients with Menorrhagia

lead_sponsor: OM PHARMA


title: A Multi-Center, Open label, Repeated Dose Range Finding Study to Evaluate the Safety, Tolerability, Immunogenicity, Pharmacokinetics and Efficacy of an Anti-IL-1β Monoclonal Antibody (ACZ885) Given Subcutaneously in Pediatric Subjects with Active Systemic Juvenile Idiopathic Arthritis (SJIA)


title:
A Randomized-Controlled Three-arm Phase II Study of Lurbinectedin (PM01183) Alone or In Combination with Gemcitabine and a control arm with Docetaxel as Second-Line Treatment in Unresectable Non-Small Cell Lung Cancer (NSCLC) Patients.

 Étude de phase II, randomisée, contrôlée, à trois bras, comparant la lurbinectedine (PM01183) seule ou en association avec la gemcitabine  versus  docétaxel comme traitement de deuxième intention chez des patients atteints de cancer bronchique non à petites cellules (CBNPC) non résécable

acronym: Not applicable

lead_sponsor: Pharma Mar S.A. Sociedad Unipersonal


title: Follow-up protocol to collect the outcome of frozen-thawed embryo transfer cycles after cryopreservation of embryos in clinical trial 107012

lead_sponsor: NV Organon


title: A Phase 2 Randomized, Multi-center, Double-blind, Vehicle-controlled, 12-Week, Safety, Efficacy, and Systemic Exposure Study followed by a 12-Week Open-label Extension of Trifarotene (CD5789) Cream HE1 in Adults and Adolescents with Autosomal Recessive Ichthyosis with Lamellar Scale

lead_sponsor: Mayne Pharma


title: A randomized, 32 week double-blind, parallel-group, multicenter study to compare the efficacy and safety of initiating treatment with combination (aliskiren/amlodipine) therapy in comparison with the sequential add-on treatment strategies in patients with essential hypertension.

acronym: ACCELERATE: Aliskiren and the Calcium Channel BlockEr amLodipine combination as an initial trEatment


title: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Crossover Trial to Evaluate the Efficacy and Tolerability of Rizatriptan 10 mg ODT for the Treatment of Acute Migraine in Patients on Topiramate for Migraine Prophylaxis

lead_sponsor: Merck & Co., Inc.


title:
An Open-Label, Multicenter, Phase 1b/2 Study of the Safety and Efficacy of TL-895 Combined with KRT-232 in Subjects with Relapsed/Refractory (R/R) FLT3+ Acute Myeloid Leukemia (AML)

 Étude de phase 1b/2, multicentrique, en ouvert visant à évaluer l'innocuité et l'efficacité du TL-895 en association avec le KRT-232 chez des patients atteints de leucémie aiguë myéloïde (LAM) FLT3+ récidivante/réfractaire (R/R)

lead_sponsor: Telios Pharma, Inc.


title: A Phase III Randomized, Placebo-Controlled Study to Evaluate the Effect of Odanacatib (MK-0822) on Bone Mineral Density (BMD) and Overall Safety, and to Estimate the Effect of Odanacatib (MK-0822) on Bone Micro-architecture in Postmenopausal Women Treated with Vitamin D

lead_sponsor: Laboratoires Merck Sharp & Dhome-Chibret


title: A Phase I/II Open-Label Dose Escalation Study to Investigate the Safety and Tolerability of Acadesine in Patients with B-Cell Chronic Lymphocytic Leukaemia

lead_sponsor: Protherics Medicines Development Ltd


title: A Phase IIa Multi-Center, Randomized, Single-Blind Safety Study of Liposomal Cyclosporine A to Treat Bronchiolitis Obliterans Syndrome Following Allogeneic Hematopoietic Stem Cell Transplantation.

lead_sponsor: Breath Therapeutics Inc.


title: A Phase 3, Multicenter, Double-Blind, Randomized, Parallel-Arm, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Adalimumab for Treatment of Nail Psoriasis in Subjects with Chronic Plaque Psoriasis

lead_sponsor: AbbVie Deutschland GmbH & Co. KG


title: An Adaptive, Randomized, Placebo-controlled, Double-blind, Multi-center Study of Oral FT-4202, a Pyruvate Kinase Activator in Patients with Sickle Cell Disease

lead_sponsor: Forma Therapeutics, Inc.


title:
An open label, multicenter roll-over extension program (REP) to characterize the long-term safety and tolerability of iptacopan (LNP023) in patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) who have completed PNH Phase 2 and Phase 3 studies with iptacopan.

 Etude d’extension en ouvert, multicentrique, ayant pour but de caractériser la tolérance et la sécurité d’emploi à long terme de l’iptacopan (LNP023) chez des patients atteints d’hémoglobinurie paroxystique nocturne (HPN) ayant terminé des études de phase II et III évaluant l’iptacopan

lead_sponsor: Novartis Pharma AG


title: "A randomized, single-blind, placebo-controlled, parallel-group study evaluating the anti-inflammatory activity of GSK315234 in synovial biopsy tissue obtained from subjects with rheumatoid arthritis"

lead_sponsor: GlaxoSmithKline Research & Development Limited


title: A phase II, randomized, partially double blind, controlled study to evaluate the immunogenicity, safety, and clinical efficacy of three doses of Neovacs’ TNF-Kinoid in adult patients with rheumatoid arthritis (RA) who have relapsed despite use of an anti-TNFα biological drug, due to anti-drug antibodies

lead_sponsor: Neovacs SA


title: A Phase 2 Clinical Study to Evaluate Daily Oral Doses of LY500307 for 24 weeks in Men with Lower Urinary Tract Symptoms (LUTS) and Prostatic Enlargement Secondary to Benign Prostatic Hyperplasia (BPH).

acronym: BPAE

lead_sponsor: Eli Lilly and Company Limited


title: First-in-human, open-label, dose-escalation trial with expansion cohorts to evaluate safety of GEN1029 in patients with malignant solid tumors

acronym: GEN1029 Safety Trial in Patients With Malignant Solid Tumors

lead_sponsor: Genmab B.V.


title: A double-blind, randomized, placebo-controlled, parallel-group, dose escalation trial to explore the potential antidyskinetic properties of safinamide in patients with Parkinson's disease suffering from levodopa induced dyskinesias.

lead_sponsor: Merck Serono S.A. - Geneva


title: Randomized Phase II study of Ixabepilone Plus Trastuzumab vs. Docetaxel Plus Trastuzumab in Female Subjects with Her2+ Locally Advanced and/or Metastatic Breast Cancer.

lead_sponsor: Bristol-Myers Squibb International Corporation


title: MULTICENTER PHASE 2 TRIAL OF ARQ 197 FOR SUBJECTS WITH RELAPSED OR REFRACTORY GERM CELL TUMORS

lead_sponsor: Daiichi Sankyo Pharma Development


title: A Double-Blind, Randomized, Crossover Trial of CSII Reservoir In-use Comparing Insulin Lispro Formulation to Insulin Aspart in Patients with Type 1 Diabetes Mellitus

lead_sponsor: Eli Lilly and Company


title: Open-label, Dose escalation, followed by Double-blind, Randomized, Two-dose, Parallel Group, Multi-center Clinical Trial of HuMax-CD4, a Fully Human Monoclonal Anti-CD4 Antibody, in Patients with Mycosis Fungoides type CTCL (stage IB-IVB) who are Refractory or Intolerant to Targretin® (bexarotene) and one other Standard Therapy

acronym: HuMax-CD4 in Refractory Mycosis Fungoides

lead_sponsor: Genmab A/S


title: A Study to Compare IPX066 and Carbidopa/Levodopa/Entacapone (CLE) in Advanced Parkinson’s Disease

lead_sponsor: Impax Laboratories, Inc., acting through its Impax Pharmaceuticals Division (Impax)


title: A Double-Masked, Placebo-Controlled, Multi-Centre, Parallel Group, Dose-Ranging Study to Assess the Efficacy and Safety of LX211 as Therapy in Subjects with Clinically Quiescent Sight Threatening, Non-Infectious Intermediate-, Anterior and Intermediate-, Posterior-, or Pan-Uveitis.

lead_sponsor: Lux Biosciences GmbH


title: A Randomized, 6-Week, Double-Blind, Placebo-controlled, Fixed-Flexible-Dose, Parallel-Group Study of Lurasidone in the Treatment of Bipolar I Depression

lead_sponsor: Dainippon Sumitomo Pharma America Inc.


title: OFA110867 : Clinical phase I/IIA study of subcutaneous administration of Ofatumumab in Rheumatoid Arthritis patients on stable dose Methotrexate

lead_sponsor: GlaxoSmithKline Research & Development Ltd


title: A Double-Blind, Placebo-Controlled, Parallel-Group, Fixed-Dosage Study to Evaluate the Efficacy and Safety of Armodafinil Treatment (150 and 200 mg/day) as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder

lead_sponsor: Cephalon, Inc.


title: A Human Clinical Trial to Evaluate the Safety and Clinical Utility of GEM OS1 as a Bone Regeneration System in Foot and Ankle Arthrodesis Procedures

lead_sponsor: BioMimetic Therapeutics, Inc


title: Nemorubicin hydrochloride (PNU-152243A) administered via intrahepatic artery in combination with cisplatin in adult patients with unresectable hepatocellular carcinoma: Phase II study preceded by dose-escalation.

lead_sponsor: Nerviano Medical Sciences S.r.l.


title: A Phase 2, Open-Label, Single-Arm, Multidose Study to Investigate the Effects of Orteronel on the QT/QTc Interval in Patients With Metastatic Castration-Resistant Prostate Cancer

lead_sponsor: Millennium Pharmaceuticals, Inc.


title: A Phase 2, Randomized, Double-blind, Placebo-controlled Study Evaluating the Safety and Efficacy of FOLFIRI in Combination With AMG 479 or AMG 655 Versus FOLFIRI for the Second-line Treatment of KRAS-mutant Metastatic Colorectal Carcinoma

lead_sponsor: Amgen Inc


title: Essai multicentrique prospectif randomisé en double aveugle contre placebo et en groupes parallèles, destiné à évaluer les effets du BF2.649 dans le traitement de la somnolence diurne excessive associée à une narcolepsie

acronym: Harmony I

lead_sponsor: Bioprojet


title: A Randomized, Double Blind Study Evaluating Tenofovir Disoproxil Fumarate (DF) Monotherapy Versus the Combination of Emtricitabine and Tenofovir DF for the Treatment of Chronic Hepatitis B

lead_sponsor: Gilead Sciences Incorporated


title: Randomised Phase III Trial of Paclitaxel plus Carboplatin (TC) Therapy versus Irinotecan plus Cisplatin (CPT-P) Therapy as a First Line Chemotherapy for Clear Cell Carcinoma of the Ovary

lead_sponsor: Kitasato institute clinical trial coordinating center


title: A Phase 2/3, Double-Blind, Randomized, Placebo-Controlled, Parallel Group, Multicenter Study to Evaluate the Efficacy and Safety of Ravulizumab in Adult Participants with Dermatomyositis.

acronym: Ravulizumab versus Placebo in Adult Participants with Dermatomyositis.

lead_sponsor: Alexion Pharmaceuticals, Inc.


title: International phase I/II expansion trial of the MEK inhibitor selumetinib in combination with dexamethasone for the treatment of relapsed/refractory RAS-pathway mutated paediatric and adult Acute Lymphoblastic Leukaemia

acronym: Seludex

lead_sponsor: University of Birmingham


title: A Randomized, Open-Label Study Comparing the Effectiveness of Olanzapine Pamoate Depot with Haloperidol Decanoate in the Treatment of Schizophrenia

acronym: HGMT

lead_sponsor: Eli Lilly and Company Limited


title:
A Phase IIIb, open-label, hybrid type III trial evaluating implementation
 strategies for long-acting cabotegravir plus long-acting rilpivirine every two months in
 HIV-1 infected, virologically suppressed adults in select European healthcare settings.

acronym: CAB And RPV Implementation Study in European Locations

lead_sponsor: Viiv Healthcare UK Limited


title: An Umbrella Study of INCMGA00012 Alone and in Combination With Other Therapies in Participants With Advanced or Metastatic Endometrial Cancer Who Have Progressed on or After Platinum-Based Chemotherapy (POD1UM-204)

lead_sponsor: Incyte Corporation


title: A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety, Tolerability, and Efficacy of AMG 827 in Subjects with Moderate to Severe Crohn’s Disease


title: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Acalabrutinib in Combination with Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Subjects ≤65 Years with Previously Untreated Non-Germinal Center Diffuse Large B-Cell Lymphoma.

acronym: ESCALADE

lead_sponsor: Acerta Pharma B.V. (A Member of the AstraZeneca Group)


title: A Dose-Ranging Study of the Efficacy, Safety, and Pharmacokinetics of Deferiprone Delayed Release Tablets in Patients with Parkinson’s Disease

lead_sponsor: ApoPharma Inc.


title: INTERVENTIONAL, NON-BLINDED, RANDOMIZED CONTROLLED MULTICENTER STUDY OF POSACONAZOLE PROPHYLAXIS FOR THE PREVENTION OF INFLUENZA-ASSOCIATED ASPERGILLOSIS (IAA) IN CRITICALLY ILL PATIENTS

acronym: POSA-FLU

lead_sponsor: UZ Leuven


title:
AN OPEN-LABEL, EXPLORATORY, MULTICENTER, EXTENSION STUDY TO EVALUATE THE LONG-TERM SAFETY, TOLERABILITY, PHARMACOKINETICS AND EFFICACY OF UCB5857 IN SUBJECTS WITH ACTIVATED PHOSPHOINOSITIDE 3 KINASE (PI3K) DELTA SYNDROME (APDS)

 ÉTUDE D’EXTENSION MULTICENTRIQUE, EXPLORATOIRE, OUVERTE, ÉVALUANT LA TOLÉRANCE À LONG TERME, LA SÉCURITÉ D’EMPLOI, LA PHARMACOCINÉTIQUE ET L’EFFICACITÉ DE L’UCB5857 CHEZ DES PATIENTS PRÉSENTANT UN SYNDROME DE PHOSPHO-INOSITIDE-3-KINASE (PI3K) DELTA ACTIVÉE (SYNDROME APDS)

lead_sponsor: UCB BioPharma SPRL


title: A PHASE III, MULTICENTER, SINGLE-ARM STUDY EVALUATING THE EFFICACY, SAFETY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF CROVALIMAB IN PEDIATRIC PATIENTS WITH ATYPICAL HEMOLYTIC UREMIC SYNDROME (aHUS)

lead_sponsor: F.Hoffmann-La Roche Ltd


title:
A Randomized, Double-Blind, Placebo-Controlled Phase II Trial of Neoadjuvant Carboplatin and Paclitaxel, With or Without Debio 1143 in Patients With Newly Diagnosed Advanced Epithelial Ovarian Cancer.

 Étude de phase II, randomisée, en double aveugle, contrôlée par placebo, portant sur le traitement néoadjuvant par carboplatine et paclitaxel, avec ou sans Debio 1143, chez des patientes atteintes d'un cancer épithélial nouvellement diagnostiqué et avancé de l'ovaire

lead_sponsor: Debiopharm International SA


title: A prospective multicentre phase II trial of zoledronic acid in patients with myelofibrosis with myeloid metaplasia (MMM)

lead_sponsor: University Hospital Leuven - Department of Haematology


title:
Phase 1/2 Study Of Intratumoral G100 With Or Without Pembrolizumab In Patients With Follicular Non-Hodgkin’s Lymphoma

 Étude de Phase I/II sur le G100 en injection intratumorale avec ou sans le pembrolizumab chez des patients porteurs de lymphome non hodgkinien folliculaire

lead_sponsor: Immune Design Ltd


title: A PHASE III, OPEN-LABEL, MULTICENTER, RANDOMIZED STUDY EVALUATING THE EFFICACY AND SAFETY OF GLOFITAMAB IN COMBINATION WITH GEMCITABINE PLUS OXALIPLATIN VERSUS RITUXIMAB IN COMBINATION WITH GEMCITABINE AND OXALIPLATIN IN PATIENTS WITH RELAPSED/REFRACTORY DIFFUSE LARGE BCELL LYMPHOMA

lead_sponsor: F. Hoffmann-La Roche Ltd


title: A Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Efficacy and Safety Study of Ezetimibe Monotherapy in Children (Ages 6 to 10 Years) With Primary Hypercholesterolemia (Heterozygous Familial and Nonfamilial)

lead_sponsor: Schering-Plough Research Institute


title:
A Phase Ib/III Randomised Study of Capivasertib plus Palbociclib and Fulvestrant versus Placebo plus Palbociclib and Fulvestrant in Hormone Receptor-Positive and Human Epidermal Growth Factor Receptor 2-Negative Locally Advanced, Unresectable or Metastatic Breast Cancer (CAPItello-292)

 Etude randomisée de phase Ib/III évaluant le Capivasertib associé au Palbociclib et Fulvestrant versus Placebo associé au Palbociclib et Fulvestrant dans le cancer du sein localement avancé, inopérable ou métastatique, positif aux récepteurs hormonaux (RH+) et négatif au récepteur de facteur de croissance épidermique humain 2 (HER2-) (CAPItello-292)

lead_sponsor: AstraZeneca AB


title:
A pragmatic adaptive randomized controlled Phase II/III multicenter study of IFX-1 in Patients with severe COVID-19 Pneumonia - "PANAMO"

 Étude de phase II/III, multicentrique, contrôlée, randomisée, adaptative, pragmatique, évaluant l’IFX-1 chez des patients atteints de pneumonie COVID-19 sévère - « PANAMO »

acronym: Panamo

lead_sponsor: InflaRx GmbH


title: A Multi-Centre, Randomized, Placebo-controlled, Parallel-Group, double-Blinded Study to Compare the Therapeutic Efficacy, Safety and Tolerability of 3 Single Vaginal Doses of Arasertaconazole Nitrate pessaries in the Treatment of Vulvovaginal Candidiasis

lead_sponsor: Ferrer Internacional, S.A


title: Randomized phase III trial on NIraparib-TSR-042 (dostarlimab) vs physician’s choice CHEmotherapy in recurrent, ovarian, fallopian tube or primary peritoneal cancer patients not candidate for platinum retreatment: NItCHE trial (MITO 33)

acronym: NItCHE

lead_sponsor: FONDAZIONE POLICLINICO UNIVERSITARIO AGOSTINO GEMELLI IRCCS UNIVERSITA' CATTOLICA DEL SACRO CUORE


title:
EPIK-P2 - A Phase II double-blind study with an upfront, 16-week randomized, placebo-controlled period, to assess the efficacy, safety and pharmacokinetics of alpelisib (BYL719) in pediatric and adult patients with PIK3CA-related overgrowth spectrum (PROS)

 EPIK-P2 : Etude de phase II avec une période initiale de 16 semaines randomisée en double aveugle contrôlée par placebo, visant à évaluer l’efficacité, la sécurité d’emploi et la pharmacocinétique d’alpelisib (BYL719) chez les patients pédiatriques et adultes atteints d’un syndrome d’hypercroissance lié à PIK3CA (PROS)

lead_sponsor: Novartis Pharma AG


title: A Phase 3, Randomized , Open-Label, Multicenter Study of the Efficacy and Safety of Pyrotinib versus Docetaxel in Patients with Advanced Non-squamous Non-small Cell Lung Cancer (NSCLC) Harboring a HER2 Exon 20 Mutation who progressed on or after Treatment with Platinum Based Chemotherapy

lead_sponsor: Jiangsu Hengrui Medicine Co., Ltd.


title:
A Phase 3 Global, Multicenter, Double-Blind Randomized Study of Carboplatin-Paclitaxel With INCMGA00012 or Placebo in Participants With Inoperable Locally Recurrent or Metastatic Squamous Cell Carcinoma of the Anal Canal Not Previously Treated With Systemic Chemotherapy (POD1UM-303/InterAACT 2)

 Étude de phase 3, internationale, multicentrique, randomisée en double aveugle, portant sur le carboplatine-paclitaxel en association avec l’INCMGA00012 ou un placebo chez des patients atteints d’un carcinome épidermoïde du canal anal métastatique ou en récidive locale non opérable, n’ayant pas été précédemment traité s par une chimiothérapie systémique (POD1UM-303/InterAACT 2)

lead_sponsor: Incyte Corporation


title: Pilot Study of Nivolumab in Pediatric Patients with Hypermutant Cancers

lead_sponsor: Hospital for Sick Children


title: A PHASE II, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY TO EVALUATE THE EFFICACY, SAFETY, AND PHARMACOKINETICS OF OBINUTUZUMAB IN ADOLESCENT PATIENTS WITH ACTIVE CLASS III OR IV LUPUS NEPHRITIS

lead_sponsor: F. Hoffman-La Roche Ltd.


title: Multi-center non-drug-interventional extension study to assess long-term safety and effects on growth in patients who received bosentan or placebo as adjunctive therapy to inhaled nitric oxide for persistent pulmonary hypertension of the newborn in FUTURE 4 (AC-052-391)

lead_sponsor: Actelion Pharmaceuticals Ltd.


title:
Vitamin D3 – Omega3 – Home Exercise – HeALTHy Ageing and Longevity
 Trial Randomized, double-blind, placebo-controlled, multi-centre clinical
 trial

 Vitamine D3 – Omega3 – Programme d’entraînement à la maison – longévité et vieillissement en bonne santé (DO-HEALTH)

acronym: DO – HEALTH

lead_sponsor: University Hospital of Zurich and City Hospital Waid


title: A Randomized, Double-Blind, Placebo-Controlled Dose Range Finding Study with Open-Label Extension to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of LMI070/branaplam when Administered as Weekly Oral Doses in Participants with Early Manifest Huntington’s Disease


title: Phase 2 single-arm studies of Temozolomide in combination with Topotecan in refractory or relapsing Neuroblastoma and Other pediatric solid tumours.

acronym: ITCC 013 - TOTEM2

lead_sponsor: Institut Gustave Roussy


title: Phase 3 study investigating the efficacy and safety of TAVT-45 (abiraterone acetate) Granules for Oral Suspension (a novel abiraterone acetate formulation) relative to a reference abiraterone acetate formulation in patients with metastatic Castrate Sensitive Prostate Cancer (mCSPC) and metastatic Castrate Resistant Prostate Cancer (mCRPC).

lead_sponsor: Tavanta Therapeutics, Inc.


title: Pregnancy and neonatal follow-up of ongoing pregnancies established after controlled ovarian stimulation in clinical trial 38825 for Org 36286 (corifollitropin alfa)

lead_sponsor: NV Organon


title: A Phase III, Multicenter, Open-Label, Extension Clinical Trial to Demonstrate the Effectiveness and Safety of Liposomal Cyclosporine A (L-CsA) Inhalation Solution Delivered via the PARI Investigational eFlow® Device plus Standard of Care in the Treatment of Bronchiolitis Obliterans Syndrome in Patients post Single or Double Lung Transplantation

lead_sponsor: BREATH Therapeutics, Inc.


title: An Open-label, International, Multi-Center, Phase I/II, Dose-escalation Trial Investigating the Safety of Zalutumumab, a Human Monoclonal Epidermal Growth Factor Receptor Antibody in Combination with Radiotherapy, in Patients with Stage III, IVa or IVb Locally Advanced Squamous Cell Carcinoma of the Head and Neck Ineligible for Platinum based Chemotherapy

acronym: Zalutumumab in combination with radiotherapy in SCCHN patients ineligible for platinum based chemoth

lead_sponsor: Genmab A/S


title: EXPLORE: A phase 2, outcomes assessor-masked, multicentre, randomised study to evaluate the safety and efficacy of two doses of GT005 administered as a single subretinal injection in subjects with geographic atrophy secondary to age-related macular degeneration

lead_sponsor: Gyroscope Therapeutics


title: A randomized, double-blind, placebo controlled, parallel group, multi-center study, to assess the safety and tolerability of 28 days treatment with NVA237 (100 or 200µg once a day) in patients with moderate to severe Chronic Obstructive Pulmonary Disease (COPD)

lead_sponsor: Novartis Pharma Services AG


title: Effectiveness of Somatostatin Analogues in Patients with hereditary hemorrhagic telangiectasia and symptomatic gastrointestinal bleeding, the SAIPAN-trial: a multicenter, randomized, open-label, parallelgroup, superiority trial.

acronym: SAIPAN-trial

lead_sponsor: Radboudumc


title: A PHASE Ib/II, OPEN-LABEL, MULTICENTER STUDY OF THE SAFETY, PHARMACOKINETICS, AND EFFICACY OF Apo2L/TRAIL ADMINISTERED INTRAVENOUSLY IN COMBINATION WITH RITUXIMAB TO SUBJECTS WITH FOLLICULAR AND OTHER LOW-GRADE, CD20+, B-CELL NON-HODGKIN’S LYMPHOMAS THAT HAVE PROGRESSED FOLLOWING PREVIOUS RITUXIMAB THERAPY

lead_sponsor: Genentech Inc.